Medidata Solutions 10-K 25 Feb 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Feb. 18, 2014	Jun. 28, 2013
Document and Entity Information [Abstract]	'	'	'
Entity Registrant Name	'Medidata Solutions, Inc.	'	'
Entity Central Index Key	'0001453814	'	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Large Accelerated Filer	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Common Stock, Shares Outstanding	'	54,171,481	'
Entity Voluntary Filers	'No	'	'
Entity Public Float	'	'	$1,667,842,781

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$22,328	$32,683
Marketable securities	218,892	89,871
Accounts receivable, net of allowance for doubtful accounts of $1,055 and $747, respectively	45,534	42,359
Prepaid commission expense	3,615	2,281
Prepaid expenses and other current assets	13,511	8,042
Deferred income taxes	665	7,465
Total current assets	304,545	182,701
Restricted cash	5,118	388
Furniture, fixtures and equipment, net	41,229	10,474
Marketable securities, long-term	195,105	0
Goodwill	15,487	15,382
Intangible assets, net	904	1,708
Deferred income taxes- long-term	345	11,055
Other assets	10,620	2,923
Total assets	573,353	224,631
Current liabilities:	'	'
Accounts payable	7,524	2,998
Accrued payroll and other compensation	27,773	14,140
Accrued expenses and other	12,265	6,729
Deferred revenue	52,628	50,348
Total current liabilities	100,190	74,215
Noncurrent liabilities:	'	'
Convertible 1.00% senior notes, net	229,705	0
Deferred revenue, less current portion	1,430	4,323
Deferred tax liabilities	5,651	624
Other long-term liabilities	10,564	3,378
Total noncurrent liabilities	247,350	8,325
Total liabilities	347,540	82,540
Commitments and contingencies	'	'
Stockholders' equity (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013):	'	'
Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and outstanding	0	0
Common stock, par value $0.01 per share; 100,000 shares authorized, 55,018 and 52,810 shares issued; 53,634 and 52,078 shares outstanding, respectively	550	528
Additional paid-in capital	248,336	160,373
Treasury stock, 1,384 and 732 shares, respectively	-26,414	-5,626
Accumulated other comprehensive loss	-199	-63
Retained earnings (accumulated deficit)	3,540	-13,121
Total stockholders' equity	225,813	142,091
Total liabilities and stockholders' equity	$573,353	$224,631

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, except Per Share data, unless otherwise specified
Accounts receivable, allowance for doubtful accounts	$1,055	$747
Preferred stock, par value	$0.01	$0.01
Preferred stock, shares authorized	5,000	5,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	55,018	52,810
Common stock, shares outstanding	53,634	52,078
Treasury stock, shares	1,384	732

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues	'	'	'
Subscription	$227,921	$171,647	$144,436
Professional services	48,928	46,700	40,023
Total revenues	276,849	218,347	184,459
Cost of revenues (1)(2)	'	'	'
Subscription	37,053	32,600	28,408
Professional services	32,856	30,062	24,423
Total cost of revenues	69,909	62,662	52,831
Gross profit	206,940	155,685	131,628
Operating costs and expenses:	'	'	'
Research and development (1)	51,202	42,276	29,568
Sales and marketing (1)(2)	66,337	47,739	36,147
General and administrative (1)	65,513	37,777	37,056
Litigation settlement	0	0	6,300
Total operating costs and expenses	183,052	127,792	109,071
Operating income	23,888	27,893	22,557
Interest and other income (expense):	'	'	'
Interest expense	-5,925	-138	-123
Interest income	555	280	293
Other (expense) income, net	-136	34	238
Total interest and other (expense) income, net	-5,506	176	408
Income before income taxes	18,382	28,069	22,965
Provision for income taxes	1,721	10,049	-16,433
Net income	16,661	18,020	39,398
Earnings per share:	'	'	'
Basic (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	$0.33	$0.37	$0.83
Diluted (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	$0.31	$0.35	$0.80
Weighted average common shares outstanding:	'	'	'
Basic (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	51,060	49,092	47,292
Diluted (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	54,118	50,938	49,314
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses	36,143	10,914	8,820
(2) Amortization of intangible assets included in cost of revenues and operating costs and expenses	804	1,792	1,589
Cost of revenues	'	'	'
Weighted average common shares outstanding:	'	'	'
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses	3,149	1,751	1,263
(2) Amortization of intangible assets included in cost of revenues and operating costs and expenses	589	1,276	1,088
Research and development	'	'	'
Weighted average common shares outstanding:	'	'	'
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses	2,397	1,049	745
Sales and marketing	'	'	'
Weighted average common shares outstanding:	'	'	'
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses	8,859	2,871	2,014
(2) Amortization of intangible assets included in cost of revenues and operating costs and expenses	215	516	501
General and administrative	'	'	'
Weighted average common shares outstanding:	'	'	'
(1) Stock-based compensation expense included in cost of revenues and operating costs and expenses	$21,738	$5,243	$4,798

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Net income	$16,661	$18,020	$39,398
Other comprehensive income (loss):	'	'	'
Foreign currency translation adjustments	-74	282	-186
Unrealized (loss) gain on marketable securities	-74	31	-59
Other comprehensive (loss) income	-148	313	-245
Income tax benefit (expense) related to unrealized gain or loss on marketable securities	12	-14	0
Other comprehensive (loss) income, net of tax	-136	299	-245
Comprehensive income, net of tax	$16,525	$18,319	$39,153

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (USD $)	Total	Common stock [Member] (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	Additional paid-in capital [Member] (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	Treasury stock [Member] (Prior period results adjusted for two-for-one stock split effected in the form of a stock dividend in December 2013)	Accumulated other comprehensive income (loss) [Member]	Accumulated deficit [Member]
In Thousands, unless otherwise specified
Stockholders' equity at Dec. 31, 2010	($51,126)	($482)	($121,774)	($474)	$117	$70,539
Shares outstanding at Dec. 31, 2010	'	48,282	'	104	'	'
Comprehensive Income:	'	'	'	'	'	'
Net income	39,398	'	'	'	0	39,398
Other comprehensive income (loss), net of tax	-245	'	'	'	-245	0
Comprehensive income, net of tax	39,153	'	'	'	-245	39,398
Stock options exercised, value	3,475	8	3,467	'	'	'
Stock options exercised, shares	'	866	'	'	'	'
Tax benefit associated with equity awards	3,255	'	3,255	'	'	'
Stock-based compensation	8,820	'	8,820	'	'	'
Nonvested restricted stock awards granted, value	0	-10	-10	'	'	'
Nonvested restricted stock awards granted, shares	'	958	'	'	'	'
Acquisition of treasury stock, value	-1,712	'	'	-1,712	'	'
Acquisition of treasury stock, shares	'	'	'	154	'	'
Nonvested restricted stock awards forfeited, value	'	'	0	0	'	'
Nonvested restricted stock awards forfeited, shares	'	'	'	72	'	'
Stockholders' equity at Dec. 31, 2011	-104,117	-500	-137,306	-2,186	362	31,141
Shares outstanding at Dec. 31, 2011	'	50,106	'	330	'	'
Comprehensive Income:	'	'	'	'	'	'
Net income	18,020	'	'	'	0	18,020
Other comprehensive income (loss), net of tax	299	'	'	'	299	0
Comprehensive income, net of tax	18,319	'	'	'	299	18,020
Stock options exercised, value	9,328	20	9,308	'	'	'
Stock options exercised, shares	'	1,890	'	'	'	'
Tax benefit associated with equity awards	2,852	'	2,852	'	'	'
Stock-based compensation	10,914	'	10,914	'	'	'
Nonvested restricted stock awards granted, value	0	-8	-8	'	'	'
Nonvested restricted stock awards granted, shares	'	814	'	'	'	'
Acquisition of treasury stock, value	-3,439	'	'	-3,439	'	'
Acquisition of treasury stock, shares	'	'	'	242	'	'
Nonvested restricted stock awards forfeited, value	'	'	-1	-1	'	'
Nonvested restricted stock awards forfeited, shares	'	'	'	160	'	'
Stockholders' equity at Dec. 31, 2012	-142,091	-528	-160,373	-5,626	63	13,121
Shares outstanding at Dec. 31, 2012	'	52,810	'	732	'	'
Comprehensive Income:	'	'	'	'	'	'
Net income	16,661	'	'	'	0	16,661
Other comprehensive income (loss), net of tax	-136	'	'	'	-136	0
Comprehensive income, net of tax	16,525	'	'	'	-136	16,661
Stock options exercised, value	10,452	13	10,439	'	'	'
Stock options exercised, shares	1,263	1,263	'	'	'	'
Tax benefit associated with equity awards	4,295	'	4,295	'	'	'
Stock-based compensation	36,143	'	36,143	'	'	'
Nonvested restricted stock awards granted, value	0	-9	-9	'	'	'
Nonvested restricted stock awards granted, shares	'	945	'	'	'	'
Acquisition of treasury stock, value	-20,787	'	'	-20,787	'	'
Acquisition of treasury stock, shares	'	'	'	466	'	'
Nonvested restricted stock awards forfeited, value	'	'	-1	-1	'	'
Nonvested restricted stock awards forfeited, shares	'	'	'	186	'	'
Equity component of convertible senior notes, net	37,094	'	37,094	'	'	'
Stockholders' equity at Dec. 31, 2013	($225,813)	($550)	($248,336)	($26,414)	$199	($3,540)
Shares outstanding at Dec. 31, 2013	'	55,018	'	1,384	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Cash flows from operating activities:	'	'	'
Net income	$16,661	$18,020	$39,398
Adjustments to reconcile net income to net cash provided by operating activities:	'	'	'
Depreciation and amortization	6,936	7,934	7,817
Stock-based compensation	36,143	10,914	8,820
Amortization of discounts or premiums on marketable securities	3,075	1,573	1,290
Deferred income taxes	-816	3,123	-21,693
Amortization of debt issuance costs	577	60	60
Amortization of debt discount	4,182	0	0
Excess tax benefit associated with equity awards	-4,531	-3,655	-3,255
Contingent consideration adjustment	239	319	223
Provision for doubtful accounts	657	165	410
Loss on fixed asset disposal	241	0	0
Changes in operating assets and liabilities:	'	'	'
Accounts receivable	1,249	-16,056	11,986
Prepaid commission expense	-535	-1,426	874
Prepaid expenses and other current assets	2,099	-2,553	1,725
Other assets	-3,697	-1,372	-505
Accounts payable	-457	-823	885
Accrued payroll and other compensation	3,614	4,286	-1,678
Accrued expenses and other	7,728	2,226	4,243
Deferred revenue	-5,465	-11,471	-21,908
Other long-term liabilities	1,697	1,981	-24
Net cash provided by operating activities	69,597	13,245	28,668
Cash flows from investing activities:	'	'	'
Purchases of furniture, fixtures and equipment	-30,505	-5,742	-4,411
Purchases of available-for-sale securities	-446,745	-109,320	-117,098
Proceeds from sale of available-for-sale securities	119,470	80,370	122,759
Acquisition of business, net of cash acquired	0	0	-5,166
Net (increase) decrease in restricted cash	-4,956	0	144
Net cash used in investing activities	-362,736	-34,692	-3,772
Cash flows from financing activities:	'	'	'
Proceeds from exercise of stock options	10,452	9,328	3,475
Excess tax benefit associated with equity awards	4,531	3,655	3,255
Payment of acquisition-related earn-out	-380	-251	0
Repayment of obligations under capital leases	-75	-268	-725
Proceeds from issuance of convertible senior notes	287,500	0	0
Payment of costs associated with issuance of convertible senior notes	-8,144	0	0
Acquisition of treasury stock	-10,828	-3,439	-1,712
Repayments of notes payable	-249	-113	0
Net cash provided by financing activities	282,807	8,912	4,293
Net (decrease) increase in cash and cash equivalents	-10,332	-12,535	29,189
Effect of exchange rate changes on cash and cash equivalents	-23	4	0
Cash and cash equivalents - Beginning of period	32,683	45,214	16,025
Cash and cash equivalents - End of period	22,328	32,683	45,214
Cash paid during the period for:	'	'	'
Interest	27	44	53
Income taxes	1,382	2,575	1,692
Noncash activities:	'	'	'
Furniture, fixtures and equipment acquired through capital lease obligations	0	26	195
Furniture, fixtures, and equipment acquired but not yet paid for at period-end	8,467	1,769	878
Issuance of notes payable in connection with acquisition-related earn-out payments	341	171	0
Contingent consideration associated with acquisition of business, at fair value	$0	$0	$1,819

Organization

Organization	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
ORGANIZATION	'
	ORGANIZATION
	Medidata Solutions, Inc. (the “Company”) provides cloud-based solutions for clinical research in life sciences, designed to transform clinical development and increase the value of its customers' research investments. The Company’s solutions allow its customers to more efficiently and effectively design, plan and manage key aspects of the clinical trial process, including study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding, clinical business analytics, and data flow and interoperability among multiple trial applications.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	Basis of Presentation—The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
	For purposes of these consolidated financial statements, the years ended December 31, 2013, 2012 and 2011 are referred to as 2013, 2012 and 2011, respectively.
	All share and per share data for all periods presented herein reflects the impact of a two-for-one stock split which was effected in the form of a stock dividend in December 2013. (See Note 3, "Stockholders Equity.")
	On the consolidated balance sheets, current and noncurrent capital lease obligations for prior periods have been reclassified to accrued expenses and other and other long-term liabilities, respectively, as capital lease obligations are no longer material to the Company's consolidated financial statements. On the consolidated statements of cash flows, the provision for doubtful accounts for prior periods has been isolated from the changes in accounts receivable to conform with the current presentation.
	Use of Estimates—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including deferred revenue, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
	Revenue Recognition—The Company derives its revenues from two sources: (1) subscription revenues, which are comprised of subscription fees from customers accessing the Company's cloud-based solutions; and (2) related professional services, such as training, implementation, interface creation, trial configuration, data testing, reporting, procedure documentation, and other customer-specific services. The Company recognizes revenues when all of the following conditions are satisfied:
	•	persuasive evidence of an arrangement exists;
	•	service has been delivered to the customer;
	•	amount of the fees to be paid by the customer is fixed or determinable; and
	•	collection of the fees is reasonably assured or probable.
	Subscription
	The Company derives its subscription revenues primarily from multi-study and single-study arrangements that grant the customer the right to use its cloud-based solutions for a specified term. Multiple study arrangements grant the customer the right to manage a predetermined number of clinical trials simultaneously for a term typically ranging from one to five years. Single-study arrangements allow customers to use the Company’s solutions on a per trial basis.
	The Company recognizes revenues in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition—SEC Materials. Revenues from subscription arrangements are recognized ratably over the term of the arrangement, beginning with the commencement of the arrangement term, which is generally aligned with the date the Company's cloud-based solutions are made available to the customer. The term of the arrangement includes optional renewal periods, if such renewal periods are likely to be exercised.
	Professional Services
	The Company also provides a range of professional services that its customers have the ability to utilize on an as-needed basis. Professional services do not result in significant alterations to the underlying solutions. When professional services are sold separate and apart from subscriptions, revenues are recognized using a proportional performance method or as services are rendered.
	In accordance with ASC 605-45, Revenue Recognition—Principal Agent Considerations, the Company included $0.7 million, $0.5 million and $0.5 million of reimbursable out-of-pocket expenses in professional services revenues in 2013, 2012 and 2011, respectively.
	Multiple-Element Arrangements
	The Company may also enter into multiple-element arrangements that combine a subscription to its cloud-based solutions with various professional services.
	The Company accounts for its multiple-element arrangements pursuant to ASC 605-25, Revenue Recognition—Multiple-Element Arrangements.
	To qualify as a separate unit of accounting under ASC 605-25, the delivered item must have value to the customer on a standalone basis. The significant deliverables under the Company’s multiple-element arrangements are subscription and professional services.
	The Company determined that subscriptions to its various cloud-based solutions are individually considered separate units of accounting. In determining whether each of its solutions has standalone value, the Company considered factors including the availability of similar solutions from other vendors, its fee structure based on inclusion and exclusion of the solution, and its marketing and delivery of the solution. The service components of the Company's cloud-based solutions, including license, delivery and support are combined and accounted for as a separate unit of accounting. The Company uses estimated selling price ("ESP") to determine the selling price for its subscriptions when sold in multiple-element arrangements, as the Company does not have vendor-specific objective evidence ("VSOE") for these subscriptions and third-party evidence ("TPE") is not a practical alternative due to differences in features and functionality as compared with other companies’ offerings.
	The Company also determined that the professional services have standalone value because those services are sold separately by other vendors. The Company uses ESP to determine the selling price for professional services when sold in multiple-element arrangements. Due to insufficient reliable pricing data, the Company is unable to establish VSOE. While other vendors offer similar services, they represent a small component of the vendor's total offerings. As a result, the Company is unable to reliably determine TPE on a standalone basis.
	The Company determines its single-point ESP for subscriptions and professional services as follows:
	•	Subscription—the Company utilizes a pricing tool that provides price quotes for its subscription configurations. Any new and potential customer subscription arrangements must be priced through the utilization of the Company’s pricing tool. The Company has established an internal committee to monitor compliance and evaluate pricing data on a periodic basis. This evaluation includes the review of actual historical pricing data, market conditions consideration and the review of pricing strategies and practices. Any necessary pricing modification made to the pricing tool is supported by the result of such evaluation. Accordingly, the Company’s ESP for subscriptions is obtained from this pricing tool.
	•	Professional services—the Company evaluates internal historical professional services pricing data to determine average pricing rates by type of professional services rendered. These averages are utilized to determine ESP for professional services, and are reviewed and updated at least annually.
	•	The Company believes the effect of changes in either the selling price, or the method, or assumptions used to determine ESP for subscriptions and professional services will not have significant effect on the allocation of the arrangement consideration as the ESP for the above deliverables are based on historical pricing data.
	The Company then allocates the arrangement consideration based on its relative ESP. Revenues for deliverables under subscriptions are recognized ratably over the term of the arrangement, beginning with the commencement of the arrangement term, which is generally aligned with the date the Company's cloud-based solutions are made available to the customer, assuming all other revenue recognition criteria are met. Revenues for deliverables under professional services are recognized using a proportional performance method or as services are rendered.
	As required by ASC 605-25, the Company continues to account for a small number of multiple-element arrangements entered into prior to 2011 as a combined single unit of accounting, which includes subscription and professional services, under the pre-amended ASC 605-25 until such arrangements expire. The related revenues are recognized ratably beginning with the commencement of the arrangement term, assuming all other remaining revenue recognition criteria are met. In addition, management’s estimate of fair value for professional services is used to derive a reasonable approximation for presenting subscription revenues and professional services revenues separately in its consolidated financial statements.
	Deferred Revenue
	Deferred revenue consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and deferred revenue. The Company invoices its customers in accordance with the terms of the underlying contract, usually in installments in advance of the related service period. Accordingly, the deferred revenue balance does not represent the total contract value of outstanding arrangements. Payment terms are typically net 30 to 45 days. Deferred revenue that is expected to be recognized during the subsequent 12-month period is recorded as current deferred revenue and the remaining portion as noncurrent deferred revenue.
	In some instances, a customer elects to renew its subscription arrangements prior to the original termination date of the arrangement. The renewed subscription agreement provides support for in-process clinical trials, and includes the right to use the Company's cloud-based solutions for initial clinical studies. As such, the unrecognized portion of the deferred revenue associated with the original arrangement is aggregated with the consideration received upon renewal and recognized as revenues over the renewed term of the subscription arrangement.
	Cost of Revenues—Cost of revenues primarily consists of costs related to delivering, maintaining and supporting the Company’s cloud-based platform and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s data center and professional services staff. Cost of revenues also includes costs associated with the Company’s data center, including networking and related depreciation expense; as well as outside service provider costs, amortization expense and general overhead. The Company allocates general overhead, such as applicable shared rent and utilities, to cost of revenues based on relative headcount.
	Software Development Costs—Costs incurred in the research and development of new software solutions and enhancements to existing software solutions are expensed as incurred under ASC 730, Research and Development. Internally developed software costs are capitalized under ASC 985-20, Software—Costs of Software to Be Sold, Leased, or Marketed, when technological feasibility is reached which is not until a working model is developed, and the functionality is tested and determined to be compliant with all federal and international regulations. As such, no internally developed software costs have been capitalized during 2013, 2012 or 2011.
	Stock-Based Compensation—The Company follows ASC 718, Compensation—Stock Compensation to account for all of its stock-based compensation plans. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes pricing model. The Company uses stock price volatility of a group of peer companies as a basis for determining the expected volatility, together with the closing prices of the Company's publicly-traded stock. Management believes this is the best estimate of the expected volatility over the weighted-average expected life of its option grants. The Company has increased the weight of its own stock price volatility within the weighted average over time as sufficient trading history is established. As the Company does not have sufficient historical exercise data in the period since its stock began being publicly traded to provide a reasonable basis upon which to estimate the expected life, the Company uses the simplified method as allowed under Securities and Exchange Commission Staff Accounting Bulletin No. 110 for estimating the expected life of options as all of its options qualify as "plain-vanilla" options. The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of the option grant with a maturity tied to the expected life of the options. No dividends are expected to be declared by the Company at this time. Compensation expense for stock options is recognized, net of estimated forfeitures, on a straight-line basis over the vesting period.
	The fair value of each nonvested restricted stock award ("RSA") is measured as if the nonvested RSA was vested and issued on the grant date. Compensation expense for RSAs is recognized, net of estimated forfeitures, on a straight-line basis over the vesting period.
	The fair value of each performance-based restricted stock unit ("PBRSU") whose vesting is dependent on the achievement of a market price target, or a "market condition," is estimated based upon the results of a Monte Carlo valuation model as of the grant date in accordance with accounting guidelines. Compensation expense related to PBRSUs with a market condition is recognized, net of estimated forfeitures, on a straight-line basis over the vesting period. The fair value of each PBRSU whose vesting is dependent on the satisfaction of a performance target, or a "performance condition," is measured as if the PBRSU was vested and issued on the grant date and adjusted in each reporting period for expected performance relative to the associated goals. Compensation expense related to PBRSUs with a performance condition is recognized when it is probable that the condition will be achieved, net of estimated forfeitures, on a straight-line basis over the vesting period. The compensation expense ultimately recognized will equal the grant date fair value for the number of shares for which the performance condition has been satisfied.
	Income Taxes—The Company uses the asset and liability method of accounting for income taxes, as prescribed by ASC 740, Income Taxes, which recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.
	All of the taxes on the Company's undistributed earnings from its foreign subsidiaries are included in U.S. current income taxes under Internal Revenue Code Section 956. As a result, no deferred income tax liability associated with the Company's undistributed earnings was recorded.
	In addition, the Company follows ASC 740-10 for the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.
	Comprehensive Income—ASC 220, Comprehensive Income, established standards for reporting and displaying comprehensive income and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company’s other comprehensive income results from foreign currency translation adjustments and unrealized holding gains and losses for investments on available-for-sale securities.
	Cash and Cash Equivalents—The Company considers all money market accounts and other highly liquid investments purchased with original maturities of three months or less to be cash and cash equivalents. The fair value of cash and cash equivalents approximates the amounts shown on the consolidated financial statements.
	Marketable Securities—In accordance with ASC 320-10, Investments-Debt and Equity Securities, and based on the Company’s intentions regarding these instruments, the Company classifies substantially all of its fixed income marketable securities as available-for-sale. Accordingly, marketable securities are reported at fair value, with all unrealized holding gains and losses reflected in stockholders’ equity. If it is determined that an investment has an other than temporary decline in fair value, the Company recognizes the investment loss in other income (expense), net in the consolidated statements of operations. The Company periodically evaluates the investments to determine if impairment charges are required.
	Accounts Receivable—Accounts receivable are recorded at original invoice amount less an allowance that management believes will be adequate to absorb estimated losses on existing accounts receivable. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience. Accounts receivable are written off when deemed uncollectible. Unbilled accounts receivable consist of revenue recognized in excess of billings, substantially all of which is expected to be billed and collected within one year. As of December 31, 2013 and 2012, unbilled accounts receivable of $9.5 million and $3.1 million, respectively, were included in accounts receivable on the Company's consolidated balance sheets.
	Prepaid Commission Expense—For arrangements where revenue is recognized over the relevant contract period, the Company capitalizes related sales commissions that have been paid and recognizes these expenses over the period the related revenue is recognized. Commissions are payable to the Company’s sales representatives upon payment from the customer. The Company amortized prepaid commissions of $11.1 million, $6.7 million and $6.7 million in 2013, 2012 and 2011, respectively, which are included within sales and marketing expense in the consolidated statements of operations. Prepaid commissions that will be recognized during the subsequent 12-month period are recorded as current prepaid commissions and the remaining portion included in other noncurrent assets.
	Restricted Cash—Restricted cash represents deposits made to fully collateralize certain standby letters of credit issued in connection with office lease arrangements. Short-term restricted cash of $0.2 million is recorded in prepaid expenses and other current assets on the Company's consolidated balance sheets as of December 31, 2013.
	Furniture, Fixtures and Equipment—Furniture, fixtures and equipment consists of furniture, computers, other office equipment, purchased software for internal use, leasehold improvements and construction in process recorded at cost. Depreciation is computed on the straight-line method over five years for furniture and fixtures, and three to five years for computer equipment and software. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. Improvements are capitalized while expenditures for repairs and maintenance are charged to expense as incurred. Construction in progress is not amortized into depreciation expense until it is placed into service.
	Goodwill and Intangible Assets—The Company has generated goodwill and certain intangible assets from various acquisitions. Goodwill represents the excess of consideration paid over the fair value of net assets acquired in business combinations. Under ASC 350-20, Goodwill and Other Intangible Assets, goodwill is evaluated for impairment using a two-step process that is performed at least annually on October 1 of each year, or whenever events or circumstances indicate that impairment may have occurred. The first step is a comparison of the fair value of an internal reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying value, goodwill of the reporting unit is not considered impaired and the second step is unnecessary. If the carrying value of the reporting unit exceeds its fair value, a second test is performed to measure the amount of impairment by comparing the carrying amount of the goodwill to a determination of the implied value of the goodwill. If the carrying amount of the goodwill is greater that the implied value, an impairment loss is recognized for the difference. The Company determined that there was no impairment of goodwill as of December 31, 2013 and 2012.
	The implied value of goodwill is determined as of the test date by performing a purchase price allocation, as if the reporting unit had just been acquired, using currently estimated fair values of the individual assets and liabilities of the reporting unit, together with an estimate of the fair value of the reporting unit taken as a whole. The estimate of the fair value of the reporting unit is based upon information available regarding the Company’s market capitalization, prices of similar groups of assets, or other valuation techniques including present value techniques based upon estimates of future cash flow.
	The definite-lived intangible assets are recorded at cost less accumulated amortization. Amortization of acquired technology and database is computed using the straight-line method over their expected useful lives, which range from five to six years, and amortization of customer relationships and customer contracts is computed using an accelerated method which reflects the pattern in which the economic benefits derived from the related intangible assets are consumed or utilized.
	Impairment of Long-Lived Assets—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such asset may be impaired. The Company subjects long-lived assets to a test of recoverability based on undiscounted cash flows expected to be generated by such assets while utilized by the Company and cash flows expected from disposition of such assets. If the assets are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Management determined that there was no impairment of long-lived assets as of December 31, 2013 and 2012.
	Convertible Notes—Pursuant to ASC 470-20, Debt—Debt with Conversion and Other Options, the Company separately accounts for the debt and conversion option components of its convertible senior notes, which permit cash settlement, in a manner that reflects the Company's nonconvertible borrowing rate at the time of issuance. The principal amount of the convertible senior notes is recorded as a liability. The value of the conversion option, net of equity issue costs, is recorded in stockholders' equity, and the offsetting debt discount is amortized to interest expense using the effective interest method over the term of the convertible senior notes. Additionally, debt issue costs are capitalized and amortized to interest expense over the term of the convertible senior notes on a straight-line basis, which approximates the effective interest method.
	Treasury Stock—Shares of the Company’s common and preferred stock that are repurchased are recorded as treasury stock at cost and included as a component of stockholders’ equity.
	Foreign Currency Translation—The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters – Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currencies of the Company’s subsidiaries in the United Kingdom and Japan are the British pound sterling and the Japanese yen, respectively. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. Foreign currency transaction gains (losses) are included in general and administrative expenses and were $(0.5) million in 2013, $0.2 million in 2012 and $(0.7) million in 2011.
	Fair Value of Financial Instruments—The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of the short maturity of these instruments. Fair values of marketable securities are based on unadjusted quoted market prices or pricing models using current market data that are observable either directly or indirectly. All methods of assessing fair value result in a general approximation of value, and such value may never actually be realized. The fair value of contingent consideration is determined based on the likelihood of contingent earn-out payments.
	Concentration of Credit Risk—Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company has policies that limit the amount of credit exposure to any one issuer. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential losses, but does not require collateral or other security to support customers’ receivables. The Company’s credit risk is further mitigated because its customer base is diversified both geographically and by industry sector.
	In 2013, 2012 and 2011, there were no significant customers that exceeded 10% of the Company's total revenues.
	Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of December 31, 2013, $26.9 million in cash and cash equivalents and restricted cash were deposited in excess of FDIC-insured limits.
	Indemnifications—The Company indemnifies its customers against claims that cloud-based solutions or services made available by the Company infringe upon a copyright, patent or the proprietary rights of others. Such indemnification provisions are disclosed in accordance with ASC 460-10-50-4, Disclosure About a Guarantor’s Obligation, as further interpreted by ASC 460-10-55-31 – 34. In the event of a claim, the Company agrees to obtain the rights for continued use of the solutions for the customer, to replace or modify the solutions or services to avoid such claim or to provide a credit to the customer for the unused portion of the subscription. A liability may be recognized under ASC 450-20, Loss Contingencies, if information prior to the issuance of the consolidated financial statements indicates that it is probable that a liability has been incurred at the balance sheet date and the amount of the loss can be reasonably estimated.
	Segment Information—As defined by ASC 280, Segment Reporting, the Company operates as a single segment, as the chief operating decision maker makes operating decisions and assesses performance based on one single operating unit. The Company recorded revenues in the following geographic areas in 2013, 2012 and 2011 (in thousands):
		2013		2012		2011
	Revenues:
	United States of America	$	197,785	$	147,165	$	118,024
Japan	32,595		28,482		25,208
Switzerland	12,682		11,598		10,522
United Kingdom	11,807		12,029		11,588
Other	21,980		19,073		19,117
Total	$	276,849	$	218,347	$	184,459
Revenues by geographic area are presented based upon the country in which revenues were generated. No individual country other than the United States, Japan, the United Kingdom, and Switzerland represented 5% or more of net revenues for any of the periods presented.
The following table summarizes long-term assets by geographic area as of December 31, 2013, 2012 and 2011 (in thousands):
	2013		2012		2011
Long-term assets:
United States of America	$	254,453	$	32,102	$	33,697
United Kingdom	10,041		9,454		7,906
Japan	4,314		374		566
Total	$	268,808	$	41,930	$	42,169
Recently Issued Accounting Pronouncements— In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. The amendments in this ASU generally represent clarification of ASC 820-10, Fair Value Measurements and Disclosures, but also include instances where a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements has changed. This ASU is the result of joint efforts by the FASB and International Accounting Standards Board to develop a single, converged fair value framework and guidance with respect to how to measure fair value and what disclosures to provide about fair value measurements. ASU No. 2011-04 is effective for interim and annual periods beginning after December 15, 2011. The Company adopted ASU No. 2011-04 on January 1, 2012, and the adoption did not have a material impact on its consolidated financial statements.
In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, which removes the presentation options contained in ASC 220, Comprehensive Income, and requires entities to report components of comprehensive income in either a continuous statement of comprehensive income or two separate but consecutive statements. Under the two-statement approach, the first statement would include components of net income, which is consistent with the format of statement of operations used today, and the second statement would include components of other comprehensive income. In December 2011, the FASB issued ASU No. 2011-12, Deferral of the Effective Date for Amendments to Presentation of Reclassification of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05, to defer indefinitely the effective date of the specific requirement to present items that are reclassified out of accumulated other comprehensive income to net income alongside their respective components of net income and other comprehensive income. All other provisions of ASU No. 2011-05 are effective for interim and annual periods beginning after December 15, 2011, and must be applied retrospectively for all periods presented in the financial statements. The Company adopted the applicable provisions of ASU No. 2011-05 on January 1, 2012. The adoption did not have a material impact on its consolidated financial statements other than a change in their presentation. In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which supersedes and replaces the presentation requirements for reclassifications out of accumulated other comprehensive income in ASU No. 2011-05 and ASU No. 2011-12. ASU No. 2013-02 is effective for reporting periods beginning after December 15, 2012. The Company adopted ASU No. 2013-02 on January 1, 2013, and the adoption did not have a material impact on its consolidated financial statements.
In September 2011, the FASB issued ASU No. 2011-08, Testing Goodwill for Impairment, which simplifies how entities test goodwill for impairment. ASU No. 2011-08 permits an entity to assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. ASU No. 2011-08 is effective for interim and financial periods beginning after December 15, 2011, with early adoption permitted. The Company adopted ASU No. 2011-08 on January 1, 2012 and the adoption did not have a material impact on its consolidated financial statements.
In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This ASU amends ASC 740, Income Taxes, to require that an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward; to the extent that a net operating loss carry forward, a similar tax loss, or a tax credit carryforward does not exist at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU No. 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. The Company will adopt ASU No. 2013-11 on January 1, 2014 and the adoption is not expected to have a material impact on its consolidated financial statements.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	STOCKHOLDERS' EQUITY
	Common Stock—Common stockholders are entitled to one vote for each share of common stock held. Common stockholders may receive dividends if and when the Board of Directors determines at its sole discretion.
	In December 2013, the Company announced a two-for-one split of its common stock, effected in the form of a stock dividend. The record date for the stock split was December 2, 2013, and the additional shares were distributed on December 16, 2013. Each shareholder of record as of the close of business on the record date received one additional share of common stock for each share held.
	Treasury Stock—From time to time, the Company grants nonvested RSAs and PBRSUs to its employees pursuant to the terms of the 2009 Long-Term Incentive Plan (the “2009 Plan”). Under the provisions of the 2009 Plan, the plan participants are allowed to cover their income tax withholding obligation through net shares upon the vesting of their RSAs or PBRSUs. On the date of vesting, the Company determines the number of shares to be withheld based on their fair value at the closing price of the Company’s common stock on the vesting date, in order to equal the amount of the plan participant's income tax withholding obligation. Those withheld shares are then held in the Company’s treasury stock at cost for future reissuance. In 2013 and 2012, the Company withheld 466,635 shares at an average price of $44.55 and 242,572 shares at an average price of $14.18, respectively, in connection with the vesting of its RSAs.

Marketable_Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2013
Marketable Securities [Abstract]	'
MARKETABLE SECURITIES	'
	MARKETABLE SECURITIES
	The Company manages its cash equivalents and marketable securities as a single investment portfolio that is intended to be available to meet the Company’s current cash requirements. Cash equivalents consist primarily of investments in money market funds. Marketable securities, which the Company classifies as available-for-sale securities, primarily consist of high quality commercial paper, corporate bonds and U.S. government debt obligations. Marketable securities with remaining effective maturities of twelve months or less from the balance sheet date are classified as short-term; otherwise, they are classified as long-term on the consolidated balance sheet.
	The following table provides the Company’s marketable securities by security type as of December 31, 2013 and 2012 (in thousands):
		As of December 31, 2013
		Cost		Gross			Gross			Estimated
				Unrealized			Unrealized			Fair
				Gains			Losses			Value
	Commercial paper and corporate bonds	$	378,135	$	122		$	(196	)	$	378,061
	U.S. government agency debt securities	35,934		3			(1		)	35,936
	Total	$	414,069	$	125		$	(197	)	$	413,997
		As of December 31, 2012
		Cost		Gross			Gross			Estimated
				Unrealized			Unrealized			Fair
				Gains			Losses			Value
	Commercial paper and corporate bonds	$	63,682	$	4		$	(11	)	$	63,675
	U.S. government agency debt securities	26,186		10			—			26,196
	Total	$	89,868	$	14		$	(11	)	$	89,871
	Contractual maturities of the Company’s marketable securities as of December 31, 2013 and 2012 are summarized as follows (in thousands):
		As of December 31, 2013					As of December 31, 2012
		Cost		Estimated Fair Value			Cost			Estimated Fair Value
	Due in one year or less	$	218,941	$	218,892		$	89,868		$	89,871
	Due in one to five years	195,128		195,105			—			—
	Total	$	414,069	$	413,997		$	89,868		$	89,871
	The following table provides the fair market value and the gross unrealized losses of the Company’s marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by security type as of December 31, 2013 and 2012 (in thousands):
		In Loss Position for Less than 12 Months
		As of December 31, 2013					As of December 31, 2012
		Fair Value		Gross			Fair Value			Gross
				Unrealized						Unrealized
				Losses						Losses
	Commercial paper and corporate bonds	$	241,381	$	(196	)	$	42,167		$	(11	)
	U.S. government agency debt securities	10,910		(1		)	—			—
	Total	$	252,291	$	(197	)	$	42,167		$	(11	)
	None of the Company’s marketable securities has been in a continuous unrealized loss position for more than twelve months as of December 31, 2013 and 2012.
	At December 31, 2013, the Company had $0.2 million of gross unrealized losses primarily due to a decrease in the fair value of certain corporate bonds. The Company regularly reviews its investment portfolio to identify and evaluate investments that have indications of possible impairment. Factors considered in determining whether a loss is temporary include:
	•	the length of time and extent to which fair value has been lower than the cost basis;
	•	the financial condition, credit quality and near-term prospects of the investee; and
	•	whether it is more likely than not that the Company will be required to sell the security prior to recovery.
	As the Company has the ability and intent to hold these investments until a recovery of fair value, which may be maturity, the Company has determined that the gross unrealized losses on such investments at December 31, 2013 are temporary in nature. Accordingly, the Company did not consider that its investments in marketable securities were other-than-temporarily impaired as of December 31, 2013.
	During 2013, 2012 and 2011, the Company recorded an insignificant amount of net realized gains or losses from the sale of marketable securities.

Fair_Value

Fair Value	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
FAIR VALUE	'
	FAIR VALUE
	ASC 820-10, Fair Value Measurements and Disclosures, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value and enhances disclosure requirements for fair value measurements. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820-10 are described as follows:
	Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
	Level 2 - Other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including:
	•	quoted prices for similar assets or liabilities in active markets;
	•	quoted prices for identical or similar assets or liabilities in markets that are not active;
	•	inputs other than quoted prices that are observable for the asset or liability; and
	•	inputs that are derived principally from or corroborated by observable market data by correlation or other means.
	If the asset or liability has a specified (contractual) term, the Level 2 inputs must be observable for substantially the full term of the asset or liability.
	Level 3 - Unobservable inputs to the valuation methodology that are significant to the fair value measurement for the asset or liability.
	Financial assets and liabilities (excluding cash balances) measured at fair value on a recurring basis as of December 31, 2013 and 2012 are summarized as follows (in thousands):
		As of December 31, 2013									As of December 31, 2012
		Fair Value Measurement Using									Fair Value Measurement Using
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Money market funds	$	751		$	—	$	—	$	751	$	17,815	$	—	$	—	$	17,815
	Corporate bonds	—			—		—		—		—		3,313		—		3,313
	Total cash equivalents	751			—		—		751		17,815		3,313		—		21,128
	Commercial paper and corporate bonds	—			378,061		—		378,061		—		63,675		—		63,675
	U.S. government agency debt securities	—			35,936		—		35,936		—		26,196		—		26,196
	Total marketable securities	—			413,997		—		413,997		—		89,871		—		89,871
	Total financial assets	$	751		$	413,997	$	—	$	414,748	$	17,815	$	93,184	$	—	$	110,999
	Liabilities:
	Contingent consideration	$	—		$	—	$	—	$	—	$	—	$	—	$	801	$	801
	The Company’s financial assets that are measured at fair value on a recurring basis are generally classified within Level 1 or Level 2 of the fair value hierarchy. Investments in money market funds have been classified as Level 1 since these securities are valued based upon $1.00 net asset value per share or unadjusted quoted prices in active markets. Investments in commercial paper, corporate bonds, and U.S. government agency debt securities have been classified as Level 2 since these securities are valued based on quoted prices in less active markets or significant inputs which are directly or indirectly observable. The valuation techniques used to measure the fair values of corporate bonds and U.S. government agency debt securities were derived from the inputs of market prices from multiple sources at each reporting period. The fair value was then determined based on a consensus price or a weighted average price for each security. For the remaining financial assets classified as Level 2, substantially all of the securities had a short maturity within one year and high credit ratings. Therefore, the valuation techniques used to measure the fair values were primarily derived from accretion of purchase price to its face value over the term of maturity or quoted market prices for similar instruments if available. During 2013 and 2012, there were no transfers of financial assets between Level 1 and Level 2.
	The contingent consideration associated with acquisition-related earn-out payments related to the acquisition of Clinical Force Limited ("Clinical Force") in July 2011 (as described in Note 6, "Acquisition"), was classified as Level 3. The fair value of the contingent consideration was estimated by applying the income approach. That measure is based on significant inputs that are not observable in the market. The significant inputs in the Level 3 measurement not supported by market activity included the Company’s probability assessments of expected future cash flows associated with its related acquisition during the earn-out payments measurement period, appropriately discounted considering the uncertainties associated with the obligation, and calculated in accordance with the terms of the purchase agreement. Significant assumptions included a discount rate of 11%, which was derived from the Company’s estimated weighted average cost of capital of 16% net of a 5% risk adjustment.
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the two years ended December 31, 2013 (in thousands):
		Contingent
		Consideration
	Balance as of January 1, 2012	$	1,522
	Change in fair value	319
	Due to sellers (included in accrued expenses and other)	(1,040		)
	Balance as of December 31, 2012	801
	Change in fair value	239
	Due to sellers (included in accrued expenses and other)	(1,040		)
	Balance as of December 31, 2013	$	—
	For the years ended December 31, 2013 and 2012, the Company recorded adjustments of $0.2 million and $0.3 million, respectively, to the contingent consideration obligation as a result of the recurring measurement of its fair value at each reporting period. The fair value adjustments were recorded in general and administrative expenses in the Company's consolidated financial statements.
	The carrying amounts of all other current financial assets and current financial liabilities reflected in the consolidated balance sheets approximate fair value due to their short-term nature. The Company does not have non-financial assets or liabilities that have been measured at fair value on a nonrecurring basis during the year ended December 31, 2013.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2013
Business Combinations [Abstract]	'
ACQUISITION	'
	ACQUISITION
	On July 1, 2011, the Company acquired Clinical Force, a UK-based provider of cloud-based clinical trial management systems (“CTMS”). In exchange for all outstanding shares of Clinical Force, the Company paid consideration consisting of $5.2 million cash at closing, plus additional performance-based earn-out payments of $2.6 million, which had a fair value of approximately $1.8 million as of the acquisition date. The earn-out payments were contingent upon the achievement of billing targets for the CTMS application, calculated over three measuring periods beginning at December 31, 2011 and continuing for each of the next two calendar years thereafter. For the measurement periods ended December 31, 2013, 2012, and 2011, the sellers earned payments of $1.1 million, $1.0 million, and $0.5 million respectively, based upon the achievement of the maximum billing targets for all three periods.
	Clinical Force's operations have been included in the Company's consolidated financial statements since the date of acquisition on July 1, 2011.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
GOODWILL AND INTANGIBLE ASSETS	'
	GOODWILL AND INTANGIBLE ASSETS
	The changes in the carrying amount of goodwill for the two years ended December 31, 2013 are as follows (in thousands).
	Balance as of January 1, 2012	$	15,164
	Foreign currency translation adjustments	218
	Balance as of December 31, 2012	15,382
	Foreign currency translation adjustments	105
	Balance as of December 31, 2013	$	15,487
	Intangible assets are summarized as follows (in thousands):
		As of December 31, 2013							As of December 31, 2012
		Gross		Accumulated			Net		Gross		Accumulated			Net
		Carrying		Amortization			Carrying		Carrying		Amortization			Carrying
		Amount					Amount		Amount					Amount
	Acquired technology	$	4,129	$	(3,481	)	$	648	$	4,094	$	(2,935	)	$	1,159
	Database	1,900		(1,900		)	—		1,900		(1,821		)	79
	Customer relationships	2,074		(1,818		)	256		2,064		(1,594		)	470
	Total	$	8,103	$	(7,199	)	$	904	$	8,058	$	(6,350	)	$	1,708
	Annual amortization for the next five years is expected to be as follows (in thousands):
	Years ending December 31,
	2014	$	551
	2015	287
	2016	47
	2017	19
	2018	—

Furniture_Fixtures_and_Equipme

Furniture, Fixtures and Equipment	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
FURNITURE, FIXTURES AND EQUIPMENT	'
	FURNITURE, FIXTURES AND EQUIPMENT
	Furniture, fixtures and equipment consist of the following (in thousands):
		As of December 31,
		2013			2012
	Computer equipment and purchased software	$	35,123		$	34,262
	Leasehold improvements	24,989			4,283
	Furniture and fixtures	4,129			1,356
	Construction in progress	2,577			2,205
	Total furniture, fixtures and equipment	66,818			42,106
	Less: accumulated depreciation and amortization	(25,589		)	(31,632		)
	Furniture, fixtures and equipment, net	$	41,229		$	10,474
	Included in furniture, fixtures and equipment, net as of December 31, 2013 and 2012 are computer equipment and purchased software acquired under capital leases of approximately $0.1 million and $0.1 million, respectively, net of related accumulated depreciation of approximately $3.3 million and $10.5 million, respectively. Total depreciation expense was $6.1 million, $6.1 million, and $6.2 million for the years ended December 31, 2013, 2012, and 2011, respectively. These amounts include depreciation of assets acquired under capital leases of $0.1 million, $0.1 million, and $0.7 million in 2013, 2012, and 2011, respectively. Assets included in construction in progress as of December 31, 2013 primarily relate to costs capitalized in connection with the Company's build-out of its newly leased office in Tokyo, Japan. Assets included in construction in progress as of December 31, 2012 primarily related to costs capitalized in connection with build-outs of the Company's new offices in the United States and United Kingdom. Capitalized costs associated with construction in progress are not amortized into depreciation expense until the related offices are occupied.

Debt

Debt	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
DEBT	'
	DEBT
	Senior Secured Credit Facility
	The senior secured credit facility, as amended ("Credit Facility"), including a $10.0 million revolving line of credit, originally entered into by the Company in September 2008 matured on September 30, 2013. The Company was in compliance with all covenants under the Credit Facility and the revolving line of credit remained undrawn throughout the entire term. The Company has decided not to renew its Credit Facility. For the three years ended December 31, 2013, the Company's interest expense related to the unused revolving credit line fee was insignificant.
	1.00% Convertible Senior Notes
	In August 2013, the Company issued at par value $287.5 million of 1.00% convertible senior notes (the "Notes"). Interest is payable semi-annually in arrears on August 1 and February 1 of each year, beginning on February 1, 2014. The Notes mature on August 1, 2018 unless repurchased or converted in accordance with their terms prior to such date. The Company may not redeem the Notes prior to their maturity date. The Notes are the Company's senior unsecured obligations and are governed by an indenture dated August 12, 2013 between the Company, as issuer, and Wells Fargo Bank, National Association, as trustee.
	Upon conversion of the Notes, the Company may choose to pay or deliver, as applicable, either cash, shares of the Company's common stock, or a combination thereof. If converted, holders of the Notes will receive, at the Company's election, cash and/or shares for the principal amount of the Notes as well as any amounts in excess of principal. The Company intends to settle the principal amount of the Notes in cash if converted.
	The initial conversion rate is 17.2286 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $58.05 per share of common stock. The conversion rate will be subject to adjustment upon occurrence of certain events, including, but not limited to, the issuance of stock dividends or payment of cash dividends on the Company's common stock (unless the holders of the Notes participate at the same time and under the same terms as the holders of common stock), or execution of a share split or share combination. Upon conversion, holders of the Notes will not receive any separate cash payment representing accrued and unpaid interest, unless conversion occurs after close of business on a regular record date and prior to the related interest payment date.
	Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding February 1, 2018 only under the following circumstances:
	•	during any calendar quarter commencing after the calendar quarter ending on December 31, 2013 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
	•	during the five business day period after any five consecutive trading day period (the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on such trading day; or
	•	upon the occurrence of certain corporate events described in the indenture governing the Notes.
	On or after February 1, 2018 until close of business on the business day immediately preceding the maturity date, holders may convert their Notes at any time, regardless of the foregoing circumstances. If the Company undergoes a fundamental change as defined in the indenture governing the Notes, holders may require the Company to repurchase for cash all of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest.
	In accounting for the issuance of the Notes, the Company separated the Notes into liability and equity components. The carrying amount of the liability component was calculated by measuring the fair value of a similar liability that does not have an associated convertible feature. The carrying amount of the equity component representing the conversion option was determined by deducting the fair value of the liability component from the par value of the Notes as a whole. The excess of the par value over the fair value of the debt represents the debt discount, which is amortized to interest expense over the term of the Notes. The equity component is not remeasured as long as it continues to meet the conditions for equity classification.
	In accounting for the $8.1 million in issuance costs related to the Note issuance, the Company allocated the total amount incurred to the liability and equity components based on their relative values. The $6.4 million in issuance costs attributed to the liability component were capitalized and are amortized to interest expense over the term of the Notes. The $1.7 million in issuance costs attributed to the equity component were netted against the equity component in additional paid-in capital. As of December 31, 2013, the unamortized debt issuance costs related to the Notes were $5.9 million. Additionally, in connection with the Notes, the Company has recorded a net deferred tax liability of $23.1 million against its additional paid-in capital primarily resulting from a basis difference associated with the liability component that represents a temporary difference for income tax purposes.
	The Notes consisted of the following as of December 31, 2013 (in thousands):
	Equity component, net of equity issue costs	$	60,222
	Liability component:
	Principal	287,500
	Less: unamortized debt discount	(57,795		)
	Net carrying amount	$	229,705
	The Notes are carried at face value less any unamortized discount, but require a disclosure of an estimate of fair value. As of December 31, 2013, the estimated fair value of the Notes is $365.1 million, which the Company considers to be a Level 2 measurement because it is based upon a recent quoted bid price for the Notes, reflecting market activity in a less than active market. As of December 31, 2013, the Notes are not convertible; however, based on the closing price of the Company's common stock on December 31, 2013 of $60.50, which exceeds their initial conversion price of $58.05, the if-converted value of the Notes exceeds their principal amount by approximately $12.2 million.
	As of December 31, 2013, the remaining life of the Notes is approximately 55 months.
	The following table sets forth total interest expense recognized related to the Notes for the year ended December 31, 2013 (in thousands except percentages):
	Contractual interest expense	$	1,118
	Amortization of debt issuance costs	533
	Amortization of debt discount	4,182
	Total	$	5,833
	Effective interest rate	6.6		%

Lease_Commitments

Lease Commitments	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
LEASE COMMITMENTS	'
	LEASE COMMITMENTS
	The Company leases certain equipment and office space under noncancelable operating lease agreements, and certain equipment under noncancelable capital lease agreements, which provide for total future minimum annual lease payments as follows (in thousands):
	Years ending December 31,	Operating Leases		Capital Leases (1)
	2014	$	9,197	$	48
	2015	12,011		34
	2016	11,099		—
	2017	11,111		—
	2018	11,260		—
	Thereafter	59,134		—
	Total minimum lease payments	$	113,812	$	82
	(1) The current and long-term portions of the Company's capital lease obligations have been recorded, net of amount representing interest, in accrued expenses and other and other long-term liabilities, respectively, on its consolidated balance sheets. Interest included in minimum annual capital lease payments was insignificant as of December 31, 2013.
	Rent expense was approximately $8.7 million in 2013, $4.8 million in 2012, and $4.1 million in 2011. The Company had several outstanding standby letters of credit issued in connection with office leases in the amount of $5.1 million and $3.9 million as of December 31, 2013 and 2012, respectively. These standby letters of credit were fully collateralized with restricted cash as of December 31, 2013 and restricted cash and revolving credit line as of December 31, 2012.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
STOCK-BASED COMPENSATION	'
	STOCK-BASED COMPENSATION
	In 2000, the Company adopted the 2000 Stock Option Plan (the “2000 Plan”). Options granted under the 2000 Plan were incentive stock options and nonqualified stock options. The majority of the options are vested 25% one year from the grant date and 75% ratably over the next three years and expire after ten years. Stock options were issued at the current estimated market price on the date of the grant. The Company does not intend to grant any additional stock options under the 2000 Plan.
	In May 2009, the Company adopted the 2009 Plan which became effective upon the completion of the IPO in June 2009. The 2009 Plan is a comprehensive incentive compensation plan under which the Company can grant equity-based and other incentive awards to employees, directors, consultants and advisors. A total of 5.0 million shares of common stock was initially reserved for issuance under the 2009 Plan, which may be in the form of stock options, nonvested RSAs and other forms of stock-based incentives, including PBRSUs, stock appreciation rights and deferred stock rights. Stock option awards are issued with an exercise price equal to the current market price on the date of the grant and vest monthly over four years. During the restriction period, nonvested RSAs are not eligible for disposition but entitle the holder to all rights of a holder of common stock, including dividends and voting rights. Nonvested RSAs and their associated dividends are subject to forfeiture under certain circumstances. Since its inception the 2009 Plan has been twice amended and restated to increase the number of shares of common stock that the Company may issue under the 2009 Plan to a total of 11.0 million shares as of December 31, 2013.
	The Company accounts for stock-based compensation in accordance with ASC 718, Compensation — Stock Compensation. For the three years ended December 31, 2013, the components of stock-based compensation expense were summarized in the following table (in thousands):
		2013			2012				2011
	Stock options	$	4,143		$	4,043			$	4,238
	Restricted stock awards	18,099			6,871				4,582
	Performance-based restricted stock units	13,901			—				—
	Total stock-based compensation	$	36,143		$	10,914			$	8,820
	Stock Options
	The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes pricing model with the following weighted-average assumptions:
		2013		2012			2011
	Expected volatility	43	%	46	%		50	%
	Expected life	6 years		6 years			6 years
	Risk-free interest rate	1.48	%	0.96	%		1.76	%
	Dividend yield	—		—			—
	The following table summarizes the status of the Company's stock options as of December 31, 2013, and changes during the year then ended (in thousands, except per share data):
		Number of		Weighted-				Weighted-		Aggregate
		Shares		Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
								(years)
	Outstanding at January 1, 2013	3,578		$	9.7
	Granted	473		42.04
	Exercised	(1,263	)	8.28
	Forfeited	(111	)	12.44
	Expired	(7	)	3.57
	Outstanding at December 31, 2013	2,670		$	16			7.31		$	118,881
	Exercisable at December 31, 2013	1,365		$	8.99			6.09		$	70,295
	Vested and expected to vest at December 31, 2013	2,594		$	15.56			7.26		$	116,637
	The weighted-average grant-date fair value of stock options granted during 2013, 2012 and 2011 was $18.06, $6.44 and $5.19 respectively. The total intrinsic value of stock options exercised during 2013, 2012 and 2011 was $38.4 million, $20.0 million and $6.2 million, respectively. As of December 31, 2013, there was a total of $12.5 million of unrecognized compensation cost related to all non-vested stock options granted, as recorded in accordance with ASC 718. This cost is expected to be recognized over a weighted-average remaining period of 2.56 years. The total fair value of stock options vested during 2013, 2012 and 2011 was $3.5 million, $3.9 million and $4.3 million, respectively.
	Restricted Stock Awards
	The following table summarizes the status of the Company’s nonvested RSAs as of December 31, 2013, and changes during the year then ended (in thousands, except per share data):
		Number of		Weighted-
		Shares		Average
				Grant-Date
				Fair Value
	Nonvested at January 1, 2013	1,945		$	11.54
	Granted	945		27.24
	Vested	(1,032	)	14.83
	Forfeited	(186	)	14.39
	Nonvested at December 31, 2013	1,672		$	18.06
	As of December 31, 2013, there was a total of $23.1 million of unrecognized compensation cost related to all nonvested RSAs granted, as recorded in accordance with ASC 718. This cost is expected to be recognized over a weighted-average remaining period of 2.20 years. The total fair value of RSAs vested during 2013, 2012 and 2011 was $44.6 million, $8.9 million and $4.8 million, respectively.
	Performance-Based Restricted Stock Units
	In February 2013, the Company began granting PBRSUs to certain employees including executives. These PBRSUs are earned upon the achievement of certain targets over a specified performance period. Each PBRSU represents a contingent right to receive one share of the Company's common stock and its fair value is based on the closing price of the Company's stock on the date of grant and adjusted for expected performance. In the case of units which vest based in whole or in part upon achievement of a market condition related to the Company's stock price, a Monte Carlo valuation model is utilized. The number of PBRSUs ultimately earned can range from zero to a specified multiple of the original award, based upon the level of performance achieved during the associated performance period in relation to the predetermined performance goals. At each reporting period, management estimates the probable number of PBRSUs that will be earned, until the final achievement is determined at the close of the respective performance periods. The resulting compensation cost is amortized net of expected forfeitures over the associated vesting period.
	Of the original target number of PBRSUs granted during 2013, which assumes performance at 100% of targeted levels, (1) 227,076 PBRSUs ("Revenue PBRSUs") have performance conditions based on revenue for the year ending December 31, 2013 relative to the Company's revenue guidance and a minimum profitability condition, vesting annually over three years commencing on the first anniversary of the grant date, with the number of PBRSUs ultimately earned ranging from zero to 200% of the original award; (2) 113,538 PBRSUs ("TSR PBRSUs") have market conditions based on the Company's total stockholder return ("TSR") relative to that of the NASDAQ Composite Index for the year ending December 31, 2013, vesting annually over three years commencing on the first anniversary of the grant date, with the number of PBRSUs ultimately earned ranging from zero to 200% of the original award; (3) 645,528 PBRSUs ("Long-Term PBRSUs") have both performance and market conditions based on the Company's compound annual growth rate of revenue ("CAGR"), as defined in the grant agreement, and the Company's absolute TSR over the three-year performance period ending December 31, 2015, vesting in full on December 31, 2015, with the number of PBRSUs ultimately earned ranging from zero to 300% of the original award; and (4) 34,426 PBRSUs ("Sales PBRSUs") have performance conditions based on the achievement of certain sales performance goals for the six months ending December 31, 2013, vesting annually over four years commencing on the first anniversary of the grant date, with the number of PBRSUs ultimately earned ranging from zero to 100% of the original award.
	The fair value of each of Revenue and Sales PBRSU is based upon the closing price of the Company's stock on the date of grant and adjusted each reporting period based on expected performance relative to the associated performance conditions.
	The fair value of each TSR and Long-Term PBRSU is estimated as of the date of grant based upon evaluation of expected performance relative to the associated market condition using a Monte Carlo valuation model with the following weighted-average assumptions:
		2013 TSR		2013 Long-Term PBRSUs
		PBRSUs
	Expected volatility - Medidata	39	%	39	%
	Expected volatility - NASDAQ Composite Index	15	%	N/A
	Risk-free interest rate	0.16	%	0.39	%
	Expected term	1.00 year		2.86 years
	With regard to the Long-Term PBRSUs, whose vesting is dependent on a performance condition related to the Company's CAGR and a market condition related to the Company's TSR over the three-year period ending December 31, 2015, the Company determined during the fourth quarter of 2013 that the achievement of the requisite performance condition is probable. As a result, the Company began recognizing the related expense in the fourth quarter of 2013.
	The following table summarizes the status of the Company’s PBRSUs based upon expected performance as of December 31, 2013, and changes during the year then ended (in thousands, except per share data):
		Revenue (1)		TSR (1)			Long-Term			Sales (1)		Total Number of Shares		Weighted-
														Average
														Grant-Date
														Fair Value
	Nonvested at January 1, 2013	—		—			—			—		—		$	—
	Granted (based on performance at 100% of targeted levels)	227		113			646			34		1,020		29.81
Adjustment related to expected performance	227		114			407			(25	)	723		28.35
Vested	—		—			—					—		—
Forfeited	—		—			(41	)		—		(41	)	30.07
Nonvested at December 31, 2013	454		227			1,012			9		1,702		$	29.18
(1) The performance period for these PBRSUs ended on December 31, 2013; subsequent to December 31, 2013, these PBRSUs are now subject only to time-based vesting over their corresponding terms.
For 2013, the Company recognized $9.3 million of expense related to the Long-Term PBRSUs, $3.3 million of expense related to the Revenue PBRSUs, $1.2 million, of expense related to the TSR PBRSUs, and $0.1 million of expense related to the Sales PBRSUs. As of December 31, 2013, there was a total of $33.1 million of unrecognized compensation cost related to all nonvested PBRSUs, as recorded in accordance with ASC 718. This cost is expected to be recognized over a weighted-average remaining period of 2.10 years.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Loss	12 Months Ended
	Dec. 31, 2013
Accumulated Other Comprehensive Income [Abstract]	'
ACCUMULATED OTHER COMPREHENSIVE LOSS	'
	ACCUMULATED OTHER COMPREHENSIVE LOSS
	The changes in the balances of each component of accumulated other comprehensive loss during the two years ended December 31, 2013 are as follows (in thousands):
		Foreign currency translation adjustments			Unrealized gains (losses) on available for sale securities			Total
	Balance as of January 1, 2012	$	(335	)	$	(27	)	$	(362	)
	Other comprehensive income, net of tax	$	282		$	17		$	299
	Balance as of December 31, 2012	$	(53	)	$	(10	)	$	(63	)
	Other comprehensive loss, net of tax	(74		)	(62		)	(136		)
	Balance as of December 31, 2013	$	(127	)	$	(72	)	$	(199	)
	For the years ended December 31, 2013 and 2012 reclassifications of items from accumulated other comprehensive loss to net income were insignificant.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
EARNINGS PER SHARE	'
	EARNINGS PER SHARE
	The Company follows ASC 260, Earnings Per Share, in calculating earnings per share. Basic earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding during the period. The holders of unvested RSAs do not have nonforfeitable rights to dividends or dividend equivalents and therefore, such vested awards do not qualify as participating securities and are excluded from the basic earnings per share calculation. Diluted earnings per share includes the determinants of basic net income per share and, in addition, gives effect to the potential dilution that would occur if securities or other contracts to issue common stock are exercised, vested or converted into common stock unless they are anti-dilutive.
	All share and per share data for all periods presented reflects the impact of a two-for-one stock split which was effected in the form of a stock dividend in December 2013. A reconciliation of the numerator and denominator of basic earnings per share and diluted earnings per share for the three years ended December 31, 2013 is shown in the following table (in thousands, except per share data):
		2013		2012		2011
	Numerator
	Numerator for basic earnings per share:
	Net income	$	16,661	$	18,020	$	39,398
	Denominator
	Denominator for basic earnings per share:
	Weighted average common shares outstanding	51,060		49,092		47,292
	Denominator for diluted earnings per share:
	Dilutive potential common shares:
	Stock options	1,581		1,290		1,520
	Nonvested restricted stock awards	1,030		556		502
	Performance-based restricted stock units	447		—		—
	Weighted average common shares outstanding with assumed conversion	54,118		50,938		49,314
	Basic earnings per share	$	0.33	$	0.37	$	0.83
	Diluted earnings per share	$	0.31	$	0.35	$	0.8
	Total number of anti-dilutive shares of stock options, nonvested restricted stock awards, and performance-based restricted stock units excluded from calculation of diluted earnings per share	237		716		972
	The effect of the Notes (see Note 9, "Debt") issued in August 2013, if any, will be reflected in diluted earnings per share using the treasury stock method as the Company intends to settle the principal amount of the Notes in cash upon conversion. During the year ended December 31, 2013, the average price of the Company's stock was below the conversion price of the Notes; as a result the Notes were not dilutive for this period.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
INCOME TAXES	'
	The components of income tax expense (benefit) for the three years ended December 31, 2013 are as follows (in thousands):
		2013			2012			2011
	Current expense:
	Federal and state	$	1,372		$	5,827		$	4,509
	Foreign	1,165			1,099			751
	Current expense	2,537			6,926			5,260
	Deferred expense (benefit):
	Federal and state	2,381			3,505			3,355
	Foreign	(439		)	(178		)	(124		)
	Valuation allowance	(2,758		)	(204		)	(24,924		)
	Deferred (benefit) expense	(816		)	3,123			(21,693		)
	Total income tax expense (benefit)	$	1,721		$	10,049		$	(16,433	)
	A reconciliation of income tax expense (benefit) and the amount computed by applying the statutory federal income tax rate to the income before provision for income taxes is as follows (in thousands):
		2013			2012			2011
	Tax computed at federal statutory rate	$	6,434		$	9,824		$	8,038
	Increase (decrease) in income taxes resulting from:
	Valuation allowance	(2,758		)	(204		)	(24,558		)
	U.S. R&D tax credit	(2,833		)	—			(2,516		)
	Recognition of uncertain tax position	269			461			342
	Stock-based compensation	(151		)	(40		)	353
	Undistributed earnings from foreign subsidiaries	1,737			1,275			665
	State tax expense, net of federal benefit	667			747			1,026
	Non-deductible bonuses	120			102			184
	Excess compensation deduction	950			—			—
	Non-deductible items	(3		)	67			(6		)
	Foreign tax rate differential	(339		)	(205		)	39
	Domestic production activities deduction	(665		)	(232		)	—
	Foreign tax credit	(1,737		)	(1,051		)	—
	Other	30			(695		)	—
	Total income tax expense (benefit)	$	1,721		$	10,049		$	(16,433	)
	As of December 31, 2013 and 2012, the components of deferred tax assets (liabilities) are as follows (in thousands):
		As of December 31,
		2013			2012
	Assets:
	Net operating loss carryforwards	$	4,961		$	5,769
	Deferred revenue	2,502			7,517
	Depreciable and amortizable assets	6,792			6,407
	U.S. and state R&D tax credits	403			281
	Foreign tax credit	107			2,758
	Stock based compensation	9,305			3,651
	Debt issuance costs	618			—
	Other	5,817			2,033
	Gross deferred tax assets	30,505			28,416
	Liabilities:
	Depreciable and amortizable assets	(12,234		)	(6,945		)
	Management fee	(222		)	(310		)
	Foreign exchange translation	(139		)	(153		)
	Convertible notes	(22,196		)	—
	Other	(355		)	(375		)
	Gross deferred tax liabilities	(35,146		)	(7,783		)
	Less: valuation allowance	—			(2,758		)
	Net deferred tax (liabilities) assets	$	(4,641	)	$	17,875
	Net current deferred tax assets	$	665		$	7,465
	Net long-term deferred tax assets	345			11,055
	Net current deferred tax liabilities (included in accrued expenses and other)	—			(21		)
	Net long-term deferred tax liabilities	(5,651		)	(624		)
	Net deferred tax (liabilities) assets	$	(4,641	)	$	17,875
	Income before provision for income taxes by jurisdiction is as follows (in thousands):
		2013			2012			2011
	U.S. income	$	14,549		$	25,064		$	21,731
	Non-U.S. income	3,833			3,005			1,234
	Total income before provision for income taxes	$	18,382		$	28,069		$	22,965
	As of December 31, 2013 and 2012, the Company had approximately $36.6 million and $12.0 million, respectively, of federal net operating loss carryforwards (“NOLs”) available to offset future taxable income expiring from 2020 through 2033. This federal NOL included $24.5 million attributable to the excess tax deductions on equity award activity which were not included in the recorded deferred tax assets as of December 31, 2013. The tax benefit of this deduction will be recognized through additional paid-in capital at such time as the federal NOL is used to reduce income taxes payable. The total amount of state and local NOLs in aggregate was $22.1 million and $12.2 million as of December 31, 2013 and 2012, respectively, expiring from 2020 through 2033. Certain NOLs obtained through the acquisition of Fast Track in 2008 are subject to limitations under Section 382 of the Internal Revenue Code.
At December 31, 2013 and 2012, the Company also had approximately $8.8 million and $4.2 million, respectively, of tax credits which were not included in the recorded deferred tax assets. The use of such credits was deferred by the excess tax deductions related to equity compensation. The tax benefit of these credits will be recognized through additional paid-in capital at such time as the credits are used to reduce income taxes payable.
As of December 31, 2013 the Company had no valuation allowance against its deferred tax assets. As of December 31, 2012, the Company maintained a valuation allowance of $2.8 million against its deferred tax asset related to foreign tax credits, as its future utilization remained uncertain. The net decreases in the valuation allowance of $2.8 million and $0.2 million in 2013 and 2012, respectively, were due primarily to the utilization of foreign tax credit carryforwards. In the fourth quarter of 2011, the Company determined that it was more likely than not that it would realize the benefit from the majority of its deferred tax assets. As a result, the Company recorded a $24.9 million reduction in valuation allowance, including a $19.0 million one-time tax benefit from the reversal of valuation allowance on the majority of the Company’s net deferred tax assets.
The Company has recorded its unrecognized tax benefits in accrued expenses and other on the accompanying consolidated balance sheet. The aggregate changes in the balance of the Company’s gross unrecognized tax benefits for the three years ended December 31, 2013 are as follows (in thousands):
	2013			2012			2011
Gross unrecognized tax benefits as of beginning of period	$	2,946		$	2,109		$	—
Increases based on tax positions related to the current year	429			229			521
Increases related to tax positions from prior fiscal years	734			608			1,588
Total gross unrecognized tax benefits as of end of period	$	4,109		$	2,946		$	2,109
As of December 31, 2013, there were $4.1 million of unrecognized benefits that would affect the Company’s effective tax rate, if recognized.
The Company recognizes accrued interest and penalties, if any, related to uncertain tax positions through income tax expense. Recognized interest and penalties were $0.2 million for 2013 and 2012 and insignificant for 2011. The Company believes that its income tax positions and deductions will be sustained on audit and does not anticipate any adjustments that will result in a material change to its financial position during the next twelve months. The Company’s federal income tax returns for the 2000 through 2012 tax years remain open to examination by the IRS in their entirety, except for its 2007 and 2010 tax returns. The examination of the Company's 2007 and 2010 federal tax returns were completed in 2010 and 2013, respectively. No adjustments to the tax returns were proposed by the IRS in either examination. In addition, the Company’s state income tax returns for the 2000 through 2012 tax years also remain open to examination by state taxing authorities.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	COMMITMENTS AND CONTINGENCIES
	401(k) Plan—The Company has a pre-tax savings and profit sharing plan (the “401(k) Plan”) under Section 401(k) of the Internal Revenue Code for substantially all employees. Under the 401(k) Plan, eligible employees are able to contribute up to 15% of their compensation not to exceed the maximum IRS annual deferral amount. The Company provides a 50% match of the first 4% of eligible compensation contributed each period by the employees. The maximum match by the Company is therefore 2% of eligible compensation. The Company incurred expense of $1.4 million, $1.2 million and $0.9 million relating to matching contributions in 2013, 2012 and 2011, respectively.
	Legal Matters—The Company is subject to legal proceedings and claims that arise in the ordinary course of business. From time to time, third parties have asserted and may in the future assert intellectual property rights to technologies that are important to the Company’s business and have demanded and may in the future demand that the Company license their technology. The Company records an estimated liability for these matters when an adverse outcome is considered to be probable and can be reasonably estimated. Although the outcome of the litigation cannot be predicted with certainty and some lawsuits, claims, or proceedings may be disposed of unfavorably to the Company, which could materially and adversely affect its financial condition or results of operations, the Company does not believe that it is currently a party to any material legal proceedings.
	On December 13, 2011, the Company entered into a settlement agreement with Datasci, LLC ("Datasci"). The settlement provided for mutual release and dismissal of all actions between the parties, and provided the Company with a non-exclusive, fully paid perpetual license to utilize the patent at issue. Under the settlement, the Company agreed to make a one-time lump sum payment to Datasci in the amount of $6.3 million to settle the claim. The entire settlement amount of $6.3 million was included in the Company’s consolidated results of operations for the year ended December 31, 2011.
	On March 4, 2011, DataTrak International, Inc. ("DataTrak") filed a complaint for alleged patent infringement against the Company in DataTrak International v. Medidata Solutions, C.A. No. 1:11-cv-00458 in the U.S. District Court for the Northern District of Ohio. The complaint asserts infringement of U.S. Patent No. 7,464,087 (the “'087 Patent”), which claims a method and system for unifying data from a variety of sources. The complaint asserts that the Company infringes upon the patent owned without providing any details concerning the alleged infringement, and it seeks unspecified damages and injunctive relief. On October 28, 2011, the Company filed an application for ex parte reexamination of the '087 Patent with the U.S. Patent and Trademark Office (the “PTO”). On December 16, 2011, the PTO issued a non-final rejection of the validity of all claims of the '087 Patent. On the same date, the district court granted the Company's motion to stay the case pending reexamination of the patent-in-suit. On April 6, 2012, the PTO issued its final office action rejecting all asserted claims of the '087 Patent. In July 2012, DataTrak filed a notice of appeal to the Board of Patent Appeals and Interferences which is still pending. If this appeal is not successful and the decision is ultimately upheld, it will result in the elimination of the litigation. The Company believes that it has valid defenses to the lawsuit and intends to defend itself vigorously in the event the stay of the case is lifted. The probability of a favorable or unfavorable outcome to the Company in the event the stay of the case is lifted is unknown nor can the liability that could potentially result from a negative outcome be reasonably estimated. As a result, the Company has not recorded any accrual associated with this litigation. Additionally, given the status of the proceedings, the complexities of the facts in dispute and the multiple claims involved, the Company is unable to estimate a range of loss related to this litigation.
	Contractual Warranties—The Company typically provides contractual warranties to its customers covering its solutions and services. To date, any refunds provided to customers have been immaterial.
	Change in Control Agreements—In January 2009, the Company entered into change in control agreements with its chief executive officer and certain other executive officers. These agreements provide for payments to be made to such officers upon involuntary termination of their employment by the Company without cause or by such officers for good reason as defined in the agreements, within a period of 2 years following a change in control. The agreements provide that, upon a qualifying termination event, such officers will be entitled to (a) a severance payment equal to the officer’s base salary plus target bonus amount; (b) continuation of health benefits for 12 months; and (c) immediate vesting of any remaining unvested equity awards, unless otherwise specified in the equity award agreements. In March 2012, the Company amended the agreements with its named executive officers to eliminate tax gross-up payments.

Unaudited_Selected_Quarterly_F

Unaudited Selected Quarterly Financial Data	12 Months Ended
	Dec. 31, 2013
Unaudited Selected Quarterly Financial Information [Abstract]	'
UNAUDITED SELECTED QUARTERLY FINANCIAL DATA	'
	UNAUDITED SELECTED QUARTERLY FINANCIAL DATA
	The following table presents the Company’s unaudited selected quarterly financial data for 2013 and 2012 (in thousands, except for share data):
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
	For the fiscal year 2013:
	Total revenues	$	63,259	$	68,069	$	70,946	$	74,575
	Gross profit	46,130		51,149		53,684		55,977
	Operating income (loss)	7,092		8,836		9,476		(1,516		)
	Net income	5,700		5,106		5,273		582
	Earnings per share:
	Basic (1)	$	0.11	$	0.1	$	0.1	$	0.01
	Diluted (1)	$	0.11	$	0.09	$	0.1	$	0.01
	For the fiscal year 2012:
	Total revenues	$	50,359	$	53,513	$	55,845	$	58,630
	Gross profit	35,744		37,738		39,946		42,257
	Operating income	6,116		5,688		6,839		9,250
	Net income	3,770		3,604		4,053		6,593
	Earnings per share:
	Basic (1)	$	0.08	$	0.07	$	0.08	$	0.13
	Diluted (1)	$	0.07	$	0.07	$	0.08	$	0.13
	(1) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock dividend in December 2013.

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts [Schedule]	12 Months Ended
	Dec. 31, 2013
Schedule II - Valuation and Qualifying Accounts [Abstract]	'
Schedule of valuation and qualifying accounts	'
	Schedule II—Valuation and Qualifying Accounts
	The allowance for doubtful accounts as of December 31, 2013 and 2012 was $1.1 million and $0.7 million, respectively. The table below details the activity in the account for the three years ended December 31, 2013 (in thousands):
		2013			2012			2011
	Balance at beginning of period	$	747		$	882		$	308
	Charged to costs and expenses	657			165			410
	Charged to other accounts	—			239			225
	Deductions	(349		)	(539		)	(61		)
	Balance at end of period	$	1,055		$	747		$	882

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of Presentation—The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). All intercompany balances and transactions have been eliminated in consolidation.
	For purposes of these consolidated financial statements, the years ended December 31, 2013, 2012 and 2011 are referred to as 2013, 2012 and 2011, respectively.
	All share and per share data for all periods presented herein reflects the impact of a two-for-one stock split which was effected in the form of a stock dividend in December 2013. (See Note 3, "Stockholders Equity.")
	On the consolidated balance sheets, current and noncurrent capital lease obligations for prior periods have been reclassified to accrued expenses and other and other long-term liabilities, respectively, as capital lease obligations are no longer material to the Company's consolidated financial statements. On the consolidated statements of cash flows, the provision for doubtful accounts for prior periods has been isolated from the changes in accounts receivable to conform with the current presentation.
Use of estimates	'
	Use of Estimates—The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including deferred revenue, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates.
Revenue recognition	'
	Revenue Recognition—The Company derives its revenues from two sources: (1) subscription revenues, which are comprised of subscription fees from customers accessing the Company's cloud-based solutions; and (2) related professional services, such as training, implementation, interface creation, trial configuration, data testing, reporting, procedure documentation, and other customer-specific services. The Company recognizes revenues when all of the following conditions are satisfied:
	•	persuasive evidence of an arrangement exists;
	•	service has been delivered to the customer;
	•	amount of the fees to be paid by the customer is fixed or determinable; and
	•	collection of the fees is reasonably assured or probable.
	Subscription
	The Company derives its subscription revenues primarily from multi-study and single-study arrangements that grant the customer the right to use its cloud-based solutions for a specified term. Multiple study arrangements grant the customer the right to manage a predetermined number of clinical trials simultaneously for a term typically ranging from one to five years. Single-study arrangements allow customers to use the Company’s solutions on a per trial basis.
	The Company recognizes revenues in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 605-10-S99, Revenue Recognition—SEC Materials. Revenues from subscription arrangements are recognized ratably over the term of the arrangement, beginning with the commencement of the arrangement term, which is generally aligned with the date the Company's cloud-based solutions are made available to the customer. The term of the arrangement includes optional renewal periods, if such renewal periods are likely to be exercised.
	Professional Services
	The Company also provides a range of professional services that its customers have the ability to utilize on an as-needed basis. Professional services do not result in significant alterations to the underlying solutions. When professional services are sold separate and apart from subscriptions, revenues are recognized using a proportional performance method or as services are rendered.
	In accordance with ASC 605-45, Revenue Recognition—Principal Agent Considerations, the Company included $0.7 million, $0.5 million and $0.5 million of reimbursable out-of-pocket expenses in professional services revenues in 2013, 2012 and 2011, respectively.
	Multiple-Element Arrangements
	The Company may also enter into multiple-element arrangements that combine a subscription to its cloud-based solutions with various professional services.
	The Company accounts for its multiple-element arrangements pursuant to ASC 605-25, Revenue Recognition—Multiple-Element Arrangements.
	To qualify as a separate unit of accounting under ASC 605-25, the delivered item must have value to the customer on a standalone basis. The significant deliverables under the Company’s multiple-element arrangements are subscription and professional services.
	The Company determined that subscriptions to its various cloud-based solutions are individually considered separate units of accounting. In determining whether each of its solutions has standalone value, the Company considered factors including the availability of similar solutions from other vendors, its fee structure based on inclusion and exclusion of the solution, and its marketing and delivery of the solution. The service components of the Company's cloud-based solutions, including license, delivery and support are combined and accounted for as a separate unit of accounting. The Company uses estimated selling price ("ESP") to determine the selling price for its subscriptions when sold in multiple-element arrangements, as the Company does not have vendor-specific objective evidence ("VSOE") for these subscriptions and third-party evidence ("TPE") is not a practical alternative due to differences in features and functionality as compared with other companies’ offerings.
	The Company also determined that the professional services have standalone value because those services are sold separately by other vendors. The Company uses ESP to determine the selling price for professional services when sold in multiple-element arrangements. Due to insufficient reliable pricing data, the Company is unable to establish VSOE. While other vendors offer similar services, they represent a small component of the vendor's total offerings. As a result, the Company is unable to reliably determine TPE on a standalone basis.
	The Company determines its single-point ESP for subscriptions and professional services as follows:
	•	Subscription—the Company utilizes a pricing tool that provides price quotes for its subscription configurations. Any new and potential customer subscription arrangements must be priced through the utilization of the Company’s pricing tool. The Company has established an internal committee to monitor compliance and evaluate pricing data on a periodic basis. This evaluation includes the review of actual historical pricing data, market conditions consideration and the review of pricing strategies and practices. Any necessary pricing modification made to the pricing tool is supported by the result of such evaluation. Accordingly, the Company’s ESP for subscriptions is obtained from this pricing tool.
	•	Professional services—the Company evaluates internal historical professional services pricing data to determine average pricing rates by type of professional services rendered. These averages are utilized to determine ESP for professional services, and are reviewed and updated at least annually.
	•	The Company believes the effect of changes in either the selling price, or the method, or assumptions used to determine ESP for subscriptions and professional services will not have significant effect on the allocation of the arrangement consideration as the ESP for the above deliverables are based on historical pricing data.
	The Company then allocates the arrangement consideration based on its relative ESP. Revenues for deliverables under subscriptions are recognized ratably over the term of the arrangement, beginning with the commencement of the arrangement term, which is generally aligned with the date the Company's cloud-based solutions are made available to the customer, assuming all other revenue recognition criteria are met. Revenues for deliverables under professional services are recognized using a proportional performance method or as services are rendered.
	As required by ASC 605-25, the Company continues to account for a small number of multiple-element arrangements entered into prior to 2011 as a combined single unit of accounting, which includes subscription and professional services, under the pre-amended ASC 605-25 until such arrangements expire. The related revenues are recognized ratably beginning with the commencement of the arrangement term, assuming all other remaining revenue recognition criteria are met. In addition, management’s estimate of fair value for professional services is used to derive a reasonable approximation for presenting subscription revenues and professional services revenues separately in its consolidated financial statements.
	Deferred Revenue
	Deferred revenue consists of billings or payments received in advance of revenue recognition and is recognized as the revenue recognition criteria are met. Amounts that have been invoiced are initially recorded in accounts receivable and deferred revenue. The Company invoices its customers in accordance with the terms of the underlying contract, usually in installments in advance of the related service period. Accordingly, the deferred revenue balance does not represent the total contract value of outstanding arrangements. Payment terms are typically net 30 to 45 days. Deferred revenue that is expected to be recognized during the subsequent 12-month period is recorded as current deferred revenue and the remaining portion as noncurrent deferred revenue.
	In some instances, a customer elects to renew its subscription arrangements prior to the original termination date of the arrangement. The renewed subscription agreement provides support for in-process clinical trials, and includes the right to use the Company's cloud-based solutions for initial clinical studies. As such, the unrecognized portion of the deferred revenue associated with the original arrangement is aggregated with the consideration received upon renewal and recognized as revenues over the renewed term of the subscription arrangement.
Cost of revenues	'
	Cost of Revenues—Cost of revenues primarily consists of costs related to delivering, maintaining and supporting the Company’s cloud-based platform and delivering professional services and support. These costs include salaries, benefits, bonuses and stock-based compensation for the Company’s data center and professional services staff. Cost of revenues also includes costs associated with the Company’s data center, including networking and related depreciation expense; as well as outside service provider costs, amortization expense and general overhead. The Company allocates general overhead, such as applicable shared rent and utilities, to cost of revenues based on relative headcount.
Software development costs	'
	Software Development Costs—Costs incurred in the research and development of new software solutions and enhancements to existing software solutions are expensed as incurred under ASC 730, Research and Development. Internally developed software costs are capitalized under ASC 985-20, Software—Costs of Software to Be Sold, Leased, or Marketed, when technological feasibility is reached which is not until a working model is developed, and the functionality is tested and determined to be compliant with all federal and international regulations. As such, no internally developed software costs have been capitalized during 2013, 2012 or 2011.
Stock-based compensation	'
	Stock-Based Compensation—The Company follows ASC 718, Compensation—Stock Compensation to account for all of its stock-based compensation plans. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes pricing model. The Company uses stock price volatility of a group of peer companies as a basis for determining the expected volatility, together with the closing prices of the Company's publicly-traded stock. Management believes this is the best estimate of the expected volatility over the weighted-average expected life of its option grants. The Company has increased the weight of its own stock price volatility within the weighted average over time as sufficient trading history is established. As the Company does not have sufficient historical exercise data in the period since its stock began being publicly traded to provide a reasonable basis upon which to estimate the expected life, the Company uses the simplified method as allowed under Securities and Exchange Commission Staff Accounting Bulletin No. 110 for estimating the expected life of options as all of its options qualify as "plain-vanilla" options. The risk-free interest rate is based on the United States Treasury yield curve in effect at the time of the option grant with a maturity tied to the expected life of the options. No dividends are expected to be declared by the Company at this time. Compensation expense for stock options is recognized, net of estimated forfeitures, on a straight-line basis over the vesting period.
	The fair value of each nonvested restricted stock award ("RSA") is measured as if the nonvested RSA was vested and issued on the grant date. Compensation expense for RSAs is recognized, net of estimated forfeitures, on a straight-line basis over the vesting period.
	The fair value of each performance-based restricted stock unit ("PBRSU") whose vesting is dependent on the achievement of a market price target, or a "market condition," is estimated based upon the results of a Monte Carlo valuation model as of the grant date in accordance with accounting guidelines. Compensation expense related to PBRSUs with a market condition is recognized, net of estimated forfeitures, on a straight-line basis over the vesting period. The fair value of each PBRSU whose vesting is dependent on the satisfaction of a performance target, or a "performance condition," is measured as if the PBRSU was vested and issued on the grant date and adjusted in each reporting period for expected performance relative to the associated goals. Compensation expense related to PBRSUs with a performance condition is recognized when it is probable that the condition will be achieved, net of estimated forfeitures, on a straight-line basis over the vesting period. The compensation expense ultimately recognized will equal the grant date fair value for the number of shares for which the performance condition has been satisfied.
Income taxes	'
	Income Taxes—The Company uses the asset and liability method of accounting for income taxes, as prescribed by ASC 740, Income Taxes, which recognizes deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.
	All of the taxes on the Company's undistributed earnings from its foreign subsidiaries are included in U.S. current income taxes under Internal Revenue Code Section 956. As a result, no deferred income tax liability associated with the Company's undistributed earnings was recorded.
	In addition, the Company follows ASC 740-10 for the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740-10, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.
Comprehensive income	'
	Comprehensive Income—ASC 220, Comprehensive Income, established standards for reporting and displaying comprehensive income and its components (revenues, expenses, gains and losses) in a full set of general-purpose financial statements. The Company’s other comprehensive income results from foreign currency translation adjustments and unrealized holding gains and losses for investments on available-for-sale securities.
Cash and cash equivalents	'
	Cash and Cash Equivalents—The Company considers all money market accounts and other highly liquid investments purchased with original maturities of three months or less to be cash and cash equivalents. The fair value of cash and cash equivalents approximates the amounts shown on the consolidated financial statements.
Marketable securities	'
	Marketable Securities—In accordance with ASC 320-10, Investments-Debt and Equity Securities, and based on the Company’s intentions regarding these instruments, the Company classifies substantially all of its fixed income marketable securities as available-for-sale. Accordingly, marketable securities are reported at fair value, with all unrealized holding gains and losses reflected in stockholders’ equity. If it is determined that an investment has an other than temporary decline in fair value, the Company recognizes the investment loss in other income (expense), net in the consolidated statements of operations. The Company periodically evaluates the investments to determine if impairment charges are required.
Accounts receivable	'
	Accounts Receivable—Accounts receivable are recorded at original invoice amount less an allowance that management believes will be adequate to absorb estimated losses on existing accounts receivable. The allowance is based on an evaluation of the collectability of accounts receivable and prior bad debt experience. Accounts receivable are written off when deemed uncollectible. Unbilled accounts receivable consist of revenue recognized in excess of billings, substantially all of which is expected to be billed and collected within one year. As of December 31, 2013 and 2012, unbilled accounts receivable of $9.5 million and $3.1 million, respectively, were included in accounts receivable on the Company's consolidated balance sheets.
Prepaid commission expense	'
	Prepaid Commission Expense—For arrangements where revenue is recognized over the relevant contract period, the Company capitalizes related sales commissions that have been paid and recognizes these expenses over the period the related revenue is recognized. Commissions are payable to the Company’s sales representatives upon payment from the customer. The Company amortized prepaid commissions of $11.1 million, $6.7 million and $6.7 million in 2013, 2012 and 2011, respectively, which are included within sales and marketing expense in the consolidated statements of operations. Prepaid commissions that will be recognized during the subsequent 12-month period are recorded as current prepaid commissions and the remaining portion included in other noncurrent assets.
Restricted cash	'
	Restricted Cash—Restricted cash represents deposits made to fully collateralize certain standby letters of credit issued in connection with office lease arrangements. Short-term restricted cash of $0.2 million is recorded in prepaid expenses and other current assets on the Company's consolidated balance sheets as of December 31, 2013.
Furniture, fixtures and equipment	'
	Furniture, Fixtures and Equipment—Furniture, fixtures and equipment consists of furniture, computers, other office equipment, purchased software for internal use, leasehold improvements and construction in process recorded at cost. Depreciation is computed on the straight-line method over five years for furniture and fixtures, and three to five years for computer equipment and software. Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. Improvements are capitalized while expenditures for repairs and maintenance are charged to expense as incurred. Construction in progress is not amortized into depreciation expense until it is placed into service.
Goodwill and intangible assets	'
	Goodwill and Intangible Assets—The Company has generated goodwill and certain intangible assets from various acquisitions. Goodwill represents the excess of consideration paid over the fair value of net assets acquired in business combinations. Under ASC 350-20, Goodwill and Other Intangible Assets, goodwill is evaluated for impairment using a two-step process that is performed at least annually on October 1 of each year, or whenever events or circumstances indicate that impairment may have occurred. The first step is a comparison of the fair value of an internal reporting unit with its carrying amount, including goodwill. If the fair value of the reporting unit exceeds its carrying value, goodwill of the reporting unit is not considered impaired and the second step is unnecessary. If the carrying value of the reporting unit exceeds its fair value, a second test is performed to measure the amount of impairment by comparing the carrying amount of the goodwill to a determination of the implied value of the goodwill. If the carrying amount of the goodwill is greater that the implied value, an impairment loss is recognized for the difference. The Company determined that there was no impairment of goodwill as of December 31, 2013 and 2012.
	The implied value of goodwill is determined as of the test date by performing a purchase price allocation, as if the reporting unit had just been acquired, using currently estimated fair values of the individual assets and liabilities of the reporting unit, together with an estimate of the fair value of the reporting unit taken as a whole. The estimate of the fair value of the reporting unit is based upon information available regarding the Company’s market capitalization, prices of similar groups of assets, or other valuation techniques including present value techniques based upon estimates of future cash flow.
	The definite-lived intangible assets are recorded at cost less accumulated amortization. Amortization of acquired technology and database is computed using the straight-line method over their expected useful lives, which range from five to six years, and amortization of customer relationships and customer contracts is computed using an accelerated method which reflects the pattern in which the economic benefits derived from the related intangible assets are consumed or utilized.
Impairment of long-lived assets	'
	Impairment of Long-Lived Assets—Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such asset may be impaired. The Company subjects long-lived assets to a test of recoverability based on undiscounted cash flows expected to be generated by such assets while utilized by the Company and cash flows expected from disposition of such assets. If the assets are impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. Management determined that there was no impairment of long-lived assets as of December 31, 2013 and 2012.
Convertible notes	'
	Convertible Notes—Pursuant to ASC 470-20, Debt—Debt with Conversion and Other Options, the Company separately accounts for the debt and conversion option components of its convertible senior notes, which permit cash settlement, in a manner that reflects the Company's nonconvertible borrowing rate at the time of issuance. The principal amount of the convertible senior notes is recorded as a liability. The value of the conversion option, net of equity issue costs, is recorded in stockholders' equity, and the offsetting debt discount is amortized to interest expense using the effective interest method over the term of the convertible senior notes. Additionally, debt issue costs are capitalized and amortized to interest expense over the term of the convertible senior notes on a straight-line basis, which approximates the effective interest method.
Treasury stock	'
	Treasury Stock—Shares of the Company’s common and preferred stock that are repurchased are recorded as treasury stock at cost and included as a component of stockholders’ equity.
Foreign currency translation	'
	Foreign Currency Translation—The financial statements of the Company’s foreign subsidiaries are translated in accordance with ASC 830-30, Foreign Currency Matters – Translation of Financial Statements. The reporting currency for the Company is the U.S. dollar. The functional currencies of the Company’s subsidiaries in the United Kingdom and Japan are the British pound sterling and the Japanese yen, respectively. Accordingly, the assets and liabilities of the Company’s foreign subsidiaries are translated into U.S. dollars using the exchange rate in effect at each balance sheet date. Revenue and expense accounts of the Company’s foreign subsidiaries are translated using an average rate of exchange during the period. Foreign currency translation adjustments are accumulated as a component of other comprehensive income (loss) as a separate component of stockholders’ equity. Gains and losses arising from transactions denominated in foreign currencies are primarily related to intercompany accounts that have been determined to be temporary in nature and accordingly, are recorded directly to the statement of operations. Foreign currency transaction gains (losses) are included in general and administrative expenses and were $(0.5) million in 2013, $0.2 million in 2012 and $(0.7) million in 2011.
Fair value of financial instruments	'
	Fair Value of Financial Instruments—The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value because of the short maturity of these instruments. Fair values of marketable securities are based on unadjusted quoted market prices or pricing models using current market data that are observable either directly or indirectly. All methods of assessing fair value result in a general approximation of value, and such value may never actually be realized. The fair value of contingent consideration is determined based on the likelihood of contingent earn-out payments.
Concentration of credit risk	'
	Concentration of Credit Risk—Financial instruments which potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, marketable securities and accounts receivable. The Company has policies that limit the amount of credit exposure to any one issuer. The Company performs ongoing credit evaluations of its customers and maintains an allowance for potential losses, but does not require collateral or other security to support customers’ receivables. The Company’s credit risk is further mitigated because its customer base is diversified both geographically and by industry sector.
	In 2013, 2012 and 2011, there were no significant customers that exceeded 10% of the Company's total revenues.
	Cash and cash equivalents and restricted cash are deposited with major financial institutions and, at times, such balances with any one financial institution may be in excess of FDIC-insured limits. As of December 31, 2013, $26.9 million in cash and cash equivalents and restricted cash were deposited in excess of FDIC-insured limits.
Indemnifications	'
	Indemnifications—The Company indemnifies its customers against claims that cloud-based solutions or services made available by the Company infringe upon a copyright, patent or the proprietary rights of others. Such indemnification provisions are disclosed in accordance with ASC 460-10-50-4, Disclosure About a Guarantor’s Obligation, as further interpreted by ASC 460-10-55-31 – 34. In the event of a claim, the Company agrees to obtain the rights for continued use of the solutions for the customer, to replace or modify the solutions or services to avoid such claim or to provide a credit to the customer for the unused portion of the subscription. A liability may be recognized under ASC 450-20, Loss Contingencies, if information prior to the issuance of the consolidated financial statements indicates that it is probable that a liability has been incurred at the balance sheet date and the amount of the loss can be reasonably estimated.
Segment information	'
	Segment Information—As defined by ASC 280, Segment Reporting, the Company operates as a single segment, as the chief operating decision maker makes operating decisions and assesses performance based on one single operating unit. The Company recorded revenues in the following geographic areas in 2013, 2012 and 2011 (in thousands):
		2013		2012		2011
	Revenues:
	United States of America	$	197,785	$	147,165	$	118,024
	Japan	32,595		28,482		25,208
	Switzerland	12,682		11,598		10,522
	United Kingdom	11,807		12,029		11,588
	Other	21,980		19,073		19,117
	Total	$	276,849	$	218,347	$	184,459
	Revenues by geographic area are presented based upon the country in which revenues were generated. No individual country other than the United States, Japan, the United Kingdom, and Switzerland represented 5% or more of net revenues for any of the periods presented.
	The following table summarizes long-term assets by geographic area as of December 31, 2013, 2012 and 2011 (in thousands):
		2013		2012		2011
	Long-term assets:
	United States of America	$	254,453	$	32,102	$	33,697
	United Kingdom	10,041		9,454		7,906
	Japan	4,314		374		566
	Total	$	268,808	$	41,930	$	42,169
Recently issued accounting pronouncements	'
	Recently Issued Accounting Pronouncements— In May 2011, the FASB issued ASU No. 2011-04, Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS. The amendments in this ASU generally represent clarification of ASC 820-10, Fair Value Measurements and Disclosures, but also include instances where a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements has changed. This ASU is the result of joint efforts by the FASB and International Accounting Standards Board to develop a single, converged fair value framework and guidance with respect to how to measure fair value and what disclosures to provide about fair value measurements. ASU No. 2011-04 is effective for interim and annual periods beginning after December 15, 2011. The Company adopted ASU No. 2011-04 on January 1, 2012, and the adoption did not have a material impact on its consolidated financial statements.
	In June 2011, the FASB issued ASU No. 2011-05, Presentation of Comprehensive Income, which removes the presentation options contained in ASC 220, Comprehensive Income, and requires entities to report components of comprehensive income in either a continuous statement of comprehensive income or two separate but consecutive statements. Under the two-statement approach, the first statement would include components of net income, which is consistent with the format of statement of operations used today, and the second statement would include components of other comprehensive income. In December 2011, the FASB issued ASU No. 2011-12, Deferral of the Effective Date for Amendments to Presentation of Reclassification of Items Out of Accumulated Other Comprehensive Income in ASU 2011-05, to defer indefinitely the effective date of the specific requirement to present items that are reclassified out of accumulated other comprehensive income to net income alongside their respective components of net income and other comprehensive income. All other provisions of ASU No. 2011-05 are effective for interim and annual periods beginning after December 15, 2011, and must be applied retrospectively for all periods presented in the financial statements. The Company adopted the applicable provisions of ASU No. 2011-05 on January 1, 2012. The adoption did not have a material impact on its consolidated financial statements other than a change in their presentation. In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income, which supersedes and replaces the presentation requirements for reclassifications out of accumulated other comprehensive income in ASU No. 2011-05 and ASU No. 2011-12. ASU No. 2013-02 is effective for reporting periods beginning after December 15, 2012. The Company adopted ASU No. 2013-02 on January 1, 2013, and the adoption did not have a material impact on its consolidated financial statements.
	In September 2011, the FASB issued ASU No. 2011-08, Testing Goodwill for Impairment, which simplifies how entities test goodwill for impairment. ASU No. 2011-08 permits an entity to assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test. ASU No. 2011-08 is effective for interim and financial periods beginning after December 15, 2011, with early adoption permitted. The Company adopted ASU No. 2011-08 on January 1, 2012 and the adoption did not have a material impact on its consolidated financial statements.
	In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. This ASU amends ASC 740, Income Taxes, to require that an unrecognized tax benefit be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward; to the extent that a net operating loss carry forward, a similar tax loss, or a tax credit carryforward does not exist at the reporting date, the unrecognized tax benefit should be presented in the financial statements as a liability and not combined with deferred tax assets. ASU No. 2013-11 is effective for interim and annual periods beginning after December 15, 2013, with early adoption permitted. The Company will adopt ASU No. 2013-11 on January 1, 2014 and the adoption is not expected to have a material impact on its consolidated financial statements.
Earnings per share	'
	The Company follows ASC 260, Earnings Per Share, in calculating earnings per share. Basic earnings per share is calculated by dividing net income available to common stockholders by the weighted-average number of shares outstanding during the period. The holders of unvested RSAs do not have nonforfeitable rights to dividends or dividend equivalents and therefore, such vested awards do not qualify as participating securities and are excluded from the basic earnings per share calculation. Diluted earnings per share includes the determinants of basic net income per share and, in addition, gives effect to the potential dilution that would occur if securities or other contracts to issue common stock are exercised, vested or converted into common stock unless they are anti-dilutive.
	All share and per share data for all periods presented reflects the impact of a two-for-one stock split which was effected in the form of a stock dividend in December 2013.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Revenues and long-term assets by geographic area	'
	The Company recorded revenues in the following geographic areas in 2013, 2012 and 2011 (in thousands):
		2013		2012		2011
	Revenues:
	United States of America	$	197,785	$	147,165	$	118,024
	Japan	32,595		28,482		25,208
	Switzerland	12,682		11,598		10,522
	United Kingdom	11,807		12,029		11,588
	Other	21,980		19,073		19,117
	Total	$	276,849	$	218,347	$	184,459
	Revenues by geographic area are presented based upon the country in which revenues were generated. No individual country other than the United States, Japan, the United Kingdom, and Switzerland represented 5% or more of net revenues for any of the periods presented.
	The following table summarizes long-term assets by geographic area as of December 31, 2013, 2012 and 2011 (in thousands):
		2013		2012		2011
	Long-term assets:
	United States of America	$	254,453	$	32,102	$	33,697
	United Kingdom	10,041		9,454		7,906
	Japan	4,314		374		566
	Total	$	268,808	$	41,930	$	42,169

Marketable_Securities_Tables

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2013
Marketable Securities [Abstract]	'
Marketable securities by security type	'
	The following table provides the Company’s marketable securities by security type as of December 31, 2013 and 2012 (in thousands):
		As of December 31, 2013
		Cost		Gross			Gross			Estimated
				Unrealized			Unrealized			Fair
				Gains			Losses			Value
	Commercial paper and corporate bonds	$	378,135	$	122		$	(196	)	$	378,061
	U.S. government agency debt securities	35,934		3			(1		)	35,936
	Total	$	414,069	$	125		$	(197	)	$	413,997
		As of December 31, 2012
		Cost		Gross			Gross			Estimated
				Unrealized			Unrealized			Fair
				Gains			Losses			Value
	Commercial paper and corporate bonds	$	63,682	$	4		$	(11	)	$	63,675
	U.S. government agency debt securities	26,186		10			—			26,196
	Total	$	89,868	$	14		$	(11	)	$	89,871
Contractual maturities of marketable securities	'
	Contractual maturities of the Company’s marketable securities as of December 31, 2013 and 2012 are summarized as follows (in thousands):
		As of December 31, 2013					As of December 31, 2012
		Cost		Estimated Fair Value			Cost			Estimated Fair Value
	Due in one year or less	$	218,941	$	218,892		$	89,868		$	89,871
	Due in one to five years	195,128		195,105			—			—
	Total	$	414,069	$	413,997		$	89,868		$	89,871
Fair market value and gross unrealized losses of marketable securities	'
	The following table provides the fair market value and the gross unrealized losses of the Company’s marketable securities with unrealized losses that are not deemed to be other-than-temporarily impaired, aggregated by security type as of December 31, 2013 and 2012 (in thousands):
		In Loss Position for Less than 12 Months
		As of December 31, 2013					As of December 31, 2012
		Fair Value		Gross			Fair Value			Gross
				Unrealized						Unrealized
				Losses						Losses
	Commercial paper and corporate bonds	$	241,381	$	(196	)	$	42,167		$	(11	)
	U.S. government agency debt securities	10,910		(1		)	—			—
	Total	$	252,291	$	(197	)	$	42,167		$	(11	)

Fair_Value_Tables

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Financial assets and liabilities measured at fair value on a recurring basis	'
	Financial assets and liabilities (excluding cash balances) measured at fair value on a recurring basis as of December 31, 2013 and 2012 are summarized as follows (in thousands):
		As of December 31, 2013									As of December 31, 2012
		Fair Value Measurement Using									Fair Value Measurement Using
		Level 1			Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
	Assets:
	Money market funds	$	751		$	—	$	—	$	751	$	17,815	$	—	$	—	$	17,815
	Corporate bonds	—			—		—		—		—		3,313		—		3,313
	Total cash equivalents	751			—		—		751		17,815		3,313		—		21,128
	Commercial paper and corporate bonds	—			378,061		—		378,061		—		63,675		—		63,675
	U.S. government agency debt securities	—			35,936		—		35,936		—		26,196		—		26,196
	Total marketable securities	—			413,997		—		413,997		—		89,871		—		89,871
	Total financial assets	$	751		$	413,997	$	—	$	414,748	$	17,815	$	93,184	$	—	$	110,999
	Liabilities:
	Contingent consideration	$	—		$	—	$	—	$	—	$	—	$	—	$	801	$	801
Summary of changes in fair value of Level 3 financial liabilities	'
	The following table provides a summary of changes in fair value of the Company’s Level 3 financial liabilities for the two years ended December 31, 2013 (in thousands):
		Contingent
		Consideration
	Balance as of January 1, 2012	$	1,522
	Change in fair value	319
	Due to sellers (included in accrued expenses and other)	(1,040		)
	Balance as of December 31, 2012	801
	Change in fair value	239
	Due to sellers (included in accrued expenses and other)	(1,040		)
	Balance as of December 31, 2013	$	—

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the carrying amount of goodwill	'
	The changes in the carrying amount of goodwill for the two years ended December 31, 2013 are as follows (in thousands).
	Balance as of January 1, 2012	$	15,164
	Foreign currency translation adjustments	218
	Balance as of December 31, 2012	15,382
	Foreign currency translation adjustments	105
	Balance as of December 31, 2013	$	15,487
Intangible assets	'
	Intangible assets are summarized as follows (in thousands):
		As of December 31, 2013							As of December 31, 2012
		Gross		Accumulated			Net		Gross		Accumulated			Net
		Carrying		Amortization			Carrying		Carrying		Amortization			Carrying
		Amount					Amount		Amount					Amount
	Acquired technology	$	4,129	$	(3,481	)	$	648	$	4,094	$	(2,935	)	$	1,159
	Database	1,900		(1,900		)	—		1,900		(1,821		)	79
	Customer relationships	2,074		(1,818		)	256		2,064		(1,594		)	470
	Total	$	8,103	$	(7,199	)	$	904	$	8,058	$	(6,350	)	$	1,708
Annual amortization for the next five years	'
	Annual amortization for the next five years is expected to be as follows (in thousands):
	Years ending December 31,
	2014	$	551
	2015	287
	2016	47
	2017	19
	2018	—

Furniture_Fixtures_and_Equipme1

Furniture, Fixtures and Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Property, Plant and Equipment [Abstract]	'
Furniture, fixtures and equipment	'
	Furniture, fixtures and equipment consist of the following (in thousands):
		As of December 31,
		2013			2012
	Computer equipment and purchased software	$	35,123		$	34,262
	Leasehold improvements	24,989			4,283
	Furniture and fixtures	4,129			1,356
	Construction in progress	2,577			2,205
	Total furniture, fixtures and equipment	66,818			42,106
	Less: accumulated depreciation and amortization	(25,589		)	(31,632		)
	Furniture, fixtures and equipment, net	$	41,229		$	10,474

Debt_Tables

Debt (Tables)	12 Months Ended
	Dec. 31, 2013
Debt Disclosure [Abstract]	'
Components of convertible senior notes	'
	The Notes consisted of the following as of December 31, 2013 (in thousands):
	Equity component, net of equity issue costs	$	60,222
	Liability component:
	Principal	287,500
	Less: unamortized debt discount	(57,795		)
	Net carrying amount	$	229,705
Interest expense related to convertible senior notes	'
	The following table sets forth total interest expense recognized related to the Notes for the year ended December 31, 2013 (in thousands except percentages):
	Contractual interest expense	$	1,118
	Amortization of debt issuance costs	533
	Amortization of debt discount	4,182
	Total	$	5,833
	Effective interest rate	6.6		%

Lease_Commitments_Tables

Lease Commitments (Tables)	12 Months Ended
	Dec. 31, 2013
Leases [Abstract]	'
Schedule of future minimum lease payments	'
	The Company leases certain equipment and office space under noncancelable operating lease agreements, and certain equipment under noncancelable capital lease agreements, which provide for total future minimum annual lease payments as follows (in thousands):
	Years ending December 31,	Operating Leases		Capital Leases (1)
	2014	$	9,197	$	48
	2015	12,011		34
	2016	11,099		—
	2017	11,111		—
	2018	11,260		—
	Thereafter	59,134		—
	Total minimum lease payments	$	113,812	$	82
	(1) The current and long-term portions of the Company's capital lease obligations have been recorded, net of amount representing interest, in accrued expenses and other and other long-term liabilities, respectively, on its consolidated balance sheets. Interest included in minimum annual capital lease payments was insignificant as of December 31, 2013.

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Components of stock-based compensation expense	'
	For the three years ended December 31, 2013, the components of stock-based compensation expense were summarized in the following table (in thousands):
		2013			2012				2011
	Stock options	$	4,143		$	4,043			$	4,238
	Restricted stock awards	18,099			6,871				4,582
	Performance-based restricted stock units	13,901			—				—
	Total stock-based compensation	$	36,143		$	10,914			$	8,820
Fair value of stock option grants	'
	The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes pricing model with the following weighted-average assumptions:
		2013		2012			2011
	Expected volatility	43	%	46	%		50	%
	Expected life	6 years		6 years			6 years
	Risk-free interest rate	1.48	%	0.96	%		1.76	%
	Dividend yield	—		—			—
Summary of activities and changes in stock option plans	'
	The following table summarizes the status of the Company's stock options as of December 31, 2013, and changes during the year then ended (in thousands, except per share data):
		Number of		Weighted-				Weighted-		Aggregate
		Shares		Average				Average		Intrinsic
				Exercise				Remaining		Value
				Price				Contractual
								Term
								(years)
	Outstanding at January 1, 2013	3,578		$	9.7
	Granted	473		42.04
	Exercised	(1,263	)	8.28
	Forfeited	(111	)	12.44
	Expired	(7	)	3.57
	Outstanding at December 31, 2013	2,670		$	16			7.31		$	118,881
	Exercisable at December 31, 2013	1,365		$	8.99			6.09		$	70,295
	Vested and expected to vest at December 31, 2013	2,594		$	15.56			7.26		$	116,637
Summary of nonvested restricted stock awards	'
	The following table summarizes the status of the Company’s nonvested RSAs as of December 31, 2013, and changes during the year then ended (in thousands, except per share data):
		Number of		Weighted-
		Shares		Average
				Grant-Date
				Fair Value
	Nonvested at January 1, 2013	1,945		$	11.54
	Granted	945		27.24
	Vested	(1,032	)	14.83
	Forfeited	(186	)	14.39
	Nonvested at December 31, 2013	1,672		$	18.06
Fair value of TSR and Long-Term PBRSUs	'
	The fair value of each TSR and Long-Term PBRSU is estimated as of the date of grant based upon evaluation of expected performance relative to the associated market condition using a Monte Carlo valuation model with the following weighted-average assumptions:
		2013 TSR		2013 Long-Term PBRSUs
		PBRSUs
	Expected volatility - Medidata	39	%	39	%
	Expected volatility - NASDAQ Composite Index	15	%	N/A
	Risk-free interest rate	0.16	%	0.39	%
	Expected term	1.00 year		2.86 years
Summary of performance-based restricted stock units based on expected performance	'
	The following table summarizes the status of the Company’s PBRSUs based upon expected performance as of December 31, 2013, and changes during the year then ended (in thousands, except per share data):
		Revenue (1)		TSR (1)			Long-Term			Sales (1)		Total Number of Shares		Weighted-
														Average
														Grant-Date
														Fair Value
	Nonvested at January 1, 2013	—		—			—			—		—		$	—
	Granted (based on performance at 100% of targeted levels)	227		113			646			34		1,020		29.81
	Adjustment related to expected performance	227		114			407			(25	)	723		28.35
	Vested	—		—			—					—		—
	Forfeited	—		—			(41	)		—		(41	)	30.07
	Nonvested at December 31, 2013	454		227			1,012			9		1,702		$	29.18
	(1) The performance period for these PBRSUs ended on December 31, 2013; subsequent to December 31, 2013, these PBRSUs are now subject only to time-based vesting over their corresponding terms.

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Loss (Tables)	12 Months Ended
	Dec. 31, 2013
Accumulated Other Comprehensive Income [Abstract]	'
Schedule of accumulated other comprehensive income (loss)	'
	The changes in the balances of each component of accumulated other comprehensive loss during the two years ended December 31, 2013 are as follows (in thousands):
		Foreign currency translation adjustments			Unrealized gains (losses) on available for sale securities			Total
	Balance as of January 1, 2012	$	(335	)	$	(27	)	$	(362	)
	Other comprehensive income, net of tax	$	282		$	17		$	299
	Balance as of December 31, 2012	$	(53	)	$	(10	)	$	(63	)
	Other comprehensive loss, net of tax	(74		)	(62		)	(136		)
	Balance as of December 31, 2013	$	(127	)	$	(72	)	$	(199	)

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Reconciliation of the numerators and denominators of basic and diluted earnings per share	'
	A reconciliation of the numerator and denominator of basic earnings per share and diluted earnings per share for the three years ended December 31, 2013 is shown in the following table (in thousands, except per share data):
		2013		2012		2011
	Numerator
	Numerator for basic earnings per share:
	Net income	$	16,661	$	18,020	$	39,398
	Denominator
	Denominator for basic earnings per share:
	Weighted average common shares outstanding	51,060		49,092		47,292
	Denominator for diluted earnings per share:
	Dilutive potential common shares:
	Stock options	1,581		1,290		1,520
	Nonvested restricted stock awards	1,030		556		502
	Performance-based restricted stock units	447		—		—
	Weighted average common shares outstanding with assumed conversion	54,118		50,938		49,314
	Basic earnings per share	$	0.33	$	0.37	$	0.83
	Diluted earnings per share	$	0.31	$	0.35	$	0.8
	Total number of anti-dilutive shares of stock options, nonvested restricted stock awards, and performance-based restricted stock units excluded from calculation of diluted earnings per share	237		716		972

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of components of income tax expense (benefit)	'
	The components of income tax expense (benefit) for the three years ended December 31, 2013 are as follows (in thousands):
		2013			2012			2011
	Current expense:
	Federal and state	$	1,372		$	5,827		$	4,509
	Foreign	1,165			1,099			751
	Current expense	2,537			6,926			5,260
	Deferred expense (benefit):
	Federal and state	2,381			3,505			3,355
	Foreign	(439		)	(178		)	(124		)
	Valuation allowance	(2,758		)	(204		)	(24,924		)
	Deferred (benefit) expense	(816		)	3,123			(21,693		)
	Total income tax expense (benefit)	$	1,721		$	10,049		$	(16,433	)
Schedule of effective income tax rate reconciliation	'
	A reconciliation of income tax expense (benefit) and the amount computed by applying the statutory federal income tax rate to the income before provision for income taxes is as follows (in thousands):
		2013			2012			2011
	Tax computed at federal statutory rate	$	6,434		$	9,824		$	8,038
	Increase (decrease) in income taxes resulting from:
	Valuation allowance	(2,758		)	(204		)	(24,558		)
	U.S. R&D tax credit	(2,833		)	—			(2,516		)
	Recognition of uncertain tax position	269			461			342
	Stock-based compensation	(151		)	(40		)	353
	Undistributed earnings from foreign subsidiaries	1,737			1,275			665
	State tax expense, net of federal benefit	667			747			1,026
	Non-deductible bonuses	120			102			184
	Excess compensation deduction	950			—			—
	Non-deductible items	(3		)	67			(6		)
	Foreign tax rate differential	(339		)	(205		)	39
	Domestic production activities deduction	(665		)	(232		)	—
	Foreign tax credit	(1,737		)	(1,051		)	—
	Other	30			(695		)	—
	Total income tax expense (benefit)	$	1,721		$	10,049		$	(16,433	)
Schedule of deferred tax assets and liabilities	'
	As of December 31, 2013 and 2012, the components of deferred tax assets (liabilities) are as follows (in thousands):
		As of December 31,
		2013			2012
	Assets:
	Net operating loss carryforwards	$	4,961		$	5,769
	Deferred revenue	2,502			7,517
	Depreciable and amortizable assets	6,792			6,407
	U.S. and state R&D tax credits	403			281
	Foreign tax credit	107			2,758
	Stock based compensation	9,305			3,651
	Debt issuance costs	618			—
	Other	5,817			2,033
	Gross deferred tax assets	30,505			28,416
	Liabilities:
	Depreciable and amortizable assets	(12,234		)	(6,945		)
	Management fee	(222		)	(310		)
	Foreign exchange translation	(139		)	(153		)
	Convertible notes	(22,196		)	—
	Other	(355		)	(375		)
	Gross deferred tax liabilities	(35,146		)	(7,783		)
	Less: valuation allowance	—			(2,758		)
	Net deferred tax (liabilities) assets	$	(4,641	)	$	17,875
	Net current deferred tax assets	$	665		$	7,465
	Net long-term deferred tax assets	345			11,055
	Net current deferred tax liabilities (included in accrued expenses and other)	—			(21		)
	Net long-term deferred tax liabilities	(5,651		)	(624		)
	Net deferred tax (liabilities) assets	$	(4,641	)	$	17,875
Schedule of income before income tax, U.S. and Non-U.S.	'
	Income before provision for income taxes by jurisdiction is as follows (in thousands):
		2013			2012			2011
	U.S. income	$	14,549		$	25,064		$	21,731
	Non-U.S. income	3,833			3,005			1,234
	Total income before provision for income taxes	$	18,382		$	28,069		$	22,965
Rollforward of unrecognized tax benefits	'
	The Company has recorded its unrecognized tax benefits in accrued expenses and other on the accompanying consolidated balance sheet. The aggregate changes in the balance of the Company’s gross unrecognized tax benefits for the three years ended December 31, 2013 are as follows (in thousands):
		2013			2012			2011
	Gross unrecognized tax benefits as of beginning of period	$	2,946		$	2,109		$	—
	Increases based on tax positions related to the current year	429			229			521
	Increases related to tax positions from prior fiscal years	734			608			1,588
	Total gross unrecognized tax benefits as of end of period	$	4,109		$	2,946		$	2,109

Unaudited_Selected_Quarterly_F1

Unaudited Selected Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2013
Unaudited Selected Quarterly Financial Information [Abstract]	'
Unaudited selected quarterly financial data	'
	The following table presents the Company’s unaudited selected quarterly financial data for 2013 and 2012 (in thousands, except for share data):
		First		Second		Third		Fourth
		Quarter		Quarter		Quarter		Quarter
	For the fiscal year 2013:
	Total revenues	$	63,259	$	68,069	$	70,946	$	74,575
	Gross profit	46,130		51,149		53,684		55,977
	Operating income (loss)	7,092		8,836		9,476		(1,516		)
	Net income	5,700		5,106		5,273		582
	Earnings per share:
	Basic (1)	$	0.11	$	0.1	$	0.1	$	0.01
	Diluted (1)	$	0.11	$	0.09	$	0.1	$	0.01
	For the fiscal year 2012:
	Total revenues	$	50,359	$	53,513	$	55,845	$	58,630
	Gross profit	35,744		37,738		39,946		42,257
	Operating income	6,116		5,688		6,839		9,250
	Net income	3,770		3,604		4,053		6,593
	Earnings per share:
	Basic (1)	$	0.08	$	0.07	$	0.08	$	0.13
	Diluted (1)	$	0.07	$	0.07	$	0.08	$	0.13
	(1) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock dividend in December 2013.

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues	$276,849	$218,347	$184,459
Specified percentage of net revenue required for separate reporting of countries' revenue	5.00%	'	'
United States of America [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues	197,785	147,165	118,024
Long-term assets	254,453	32,102	33,697
Japan [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues	32,595	28,482	25,208
Long-term assets	4,314	374	566
Switzerland [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues	12,682	11,598	10,522
United Kingdom [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues	11,807	12,029	11,588
Long-term assets	10,041	9,454	7,906
Other [Member]	'	'	'
Revenues from External Customers and Long-Lived Assets [Line Items]	'	'	'
Revenues	$21,980	$19,073	$19,117

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
[Line Items]	'	'	'
Reimbursable expenses included in professional services revenues	$0.70	$0.50	$0.50
Typical invoice payment terms	'net 30 to 45 days	'	'
Internally developed software costs capitalized	0	0	0
Unbilled receivables	9.5	3.1	'
Amortization of prepaid commission expense	11.1	6.7	6.7
Restricted cash, short-term	0.2	'	'
Foreign currency transaction gains (losses)	-0.5	0.2	-0.7
Disclosure of major customers	'In 2013, 2012 and 2011, there were no significant customers that exceeded 10% of the Company's total revenues.	'	'
Cash in excess of FDIC-insured limits	$26.90	'	'
Specified percentage of revenue to be considered significant customer	10.00%	'	'
Computer equipment and software [Member]	'	'	'
[Line Items]	'	'	'
Minimum useful life (years)	'3 years	'	'
Maximum useful life (years)	'5 years	'	'
Furniture and fixtures [Member]	'	'	'
[Line Items]	'	'	'
Useful life (years)	'5 years	'	'

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Stockholders' Equity Note [Abstract]	'	'
Stock split ratio	2	'
Description of stock split	'effected in the form of a stock dividend. The record date for the stock split was December 2, 2013, and the additional shares were distributed on December 16, 2013. Each shareholder of record as of the close of business on the record date received one additional share of common stock for each share held.	'
Shares paid for tax withholding for share based compensation	466,635	242,572
Shares paid for tax withholding for share based compensation, average price	$44.55	$14.18

Marketable_Securities_Details

Marketable Securities (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Marketable securities by security type	'	'
Cost	$414,069	$89,868
Gross unrealized gains	125	14
Gross unrealized losses	-197	-11
Estimated fair value	413,997	89,871
Commercial paper and corporate bonds [Member]	'	'
Marketable securities by security type	'	'
Cost	378,135	63,682
Gross unrealized gains	122	4
Gross unrealized losses	-196	-11
Estimated fair value	378,061	63,675
U.S. government agency debt securities [Member]	'	'
Marketable securities by security type	'	'
Cost	35,934	26,186
Gross unrealized gains	3	10
Gross unrealized losses	-1	0
Estimated fair value	$35,936	$26,196

Marketable_Securities_Details_

Marketable Securities (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Marketable securities by contractual maturity	'	'
Cost	$414,069	$89,868
Estimated fair value	413,997	89,871
One year or less [Member]	'	'
Marketable securities by contractual maturity	'	'
Cost	218,941	89,868
Estimated fair value	218,892	89,871
One to five years [Member]	'	'
Marketable securities by contractual maturity	'	'
Cost	195,128	0
Estimated fair value	$195,105	$0

Marketable_Securities_Details_1

Marketable Securities (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair market value and gross unrealized losses of marketable securities	'	'
Fair Value	$252,291	$42,167
Gross Unrealized Losses	-197	-11
Commercial paper and corporate bonds [Member]	'	'
Fair market value and gross unrealized losses of marketable securities	'	'
Fair Value	241,381	42,167
Gross Unrealized Losses	-196	-11
U.S. government agency debt securities [Member]	'	'
Fair market value and gross unrealized losses of marketable securities	'	'
Fair Value	10,910	0
Gross Unrealized Losses	($1)	$0

Marketable_Securities_Details_2

Marketable Securities (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Marketable Securities (Textual)	'	'	'
Net realized gains (losses) from the sale of marketable securities	$2	$0	$0

Fair_Value_Details

Fair Value (Details) (Fair value, recurring [Member], USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets	'	'
Cash equivalents	$751	$21,128
Total marketable securities	413,997	89,871
Total financial assets	414,748	110,999
Money market funds [Member]	'	'
Assets	'	'
Cash equivalents	751	17,815
Commercial paper [Member]	'	'
Assets	'	'
Cash equivalents	0	3,313
Commercial paper and corporate bonds [Member]	'	'
Assets	'	'
Total marketable securities	378,061	63,675
U.S. government agency debt securities [Member]	'	'
Assets	'	'
Total marketable securities	35,936	26,196
Contingent consideration [Member]	'	'
Liabilities	'	'
Contingent consideration	0	801
Level 1 [Member]	'	'
Assets	'	'
Cash equivalents	751	17,815
Total marketable securities	0	0
Total financial assets	751	17,815
Level 1 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash equivalents	751	17,815
Level 1 [Member] | Commercial paper [Member]	'	'
Assets	'	'
Cash equivalents	0	0
Level 1 [Member] | Commercial paper and corporate bonds [Member]	'	'
Assets	'	'
Total marketable securities	0	0
Level 1 [Member] | U.S. government agency debt securities [Member]	'	'
Assets	'	'
Total marketable securities	0	0
Level 1 [Member] | Contingent consideration [Member]	'	'
Liabilities	'	'
Contingent consideration	0	0
Level 2 [Member]	'	'
Assets	'	'
Cash equivalents	0	3,313
Total marketable securities	413,997	89,871
Total financial assets	413,997	93,184
Level 2 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash equivalents	0	0
Level 2 [Member] | Commercial paper [Member]	'	'
Assets	'	'
Cash equivalents	0	3,313
Level 2 [Member] | Commercial paper and corporate bonds [Member]	'	'
Assets	'	'
Total marketable securities	378,061	63,675
Level 2 [Member] | U.S. government agency debt securities [Member]	'	'
Assets	'	'
Total marketable securities	35,936	26,196
Level 2 [Member] | Contingent consideration [Member]	'	'
Liabilities	'	'
Contingent consideration	0	0
Level 3 [Member]	'	'
Assets	'	'
Cash equivalents	0	0
Total marketable securities	0	0
Total financial assets	0	0
Level 3 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash equivalents	0	0
Level 3 [Member] | Commercial paper [Member]	'	'
Assets	'	'
Cash equivalents	0	0
Level 3 [Member] | Commercial paper and corporate bonds [Member]	'	'
Assets	'	'
Total marketable securities	0	0
Level 3 [Member] | U.S. government agency debt securities [Member]	'	'
Assets	'	'
Total marketable securities	0	0
Level 3 [Member] | Contingent consideration [Member]	'	'
Liabilities	'	'
Contingent consideration	$0	$801

Fair_Value_Details_1

Fair Value (Details 1) (Fair value, recurring [Member], Level 3 [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Fair value, recurring [Member] | Level 3 [Member]	'	'
Summary of changes in fair value of contingent consideration	'	'
Beginning balance	$801	$1,522
Change in fair value	239	319
Due to sellers (included in accrued expenses and other)	-1,040	-1,040
Ending balance	$0	$801

Fair_Value_Details_Textual

Fair Value (Details Textual) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Fair value (Textual) [Abstract]	'
Net asset value per share used to value money market securities	$1
Transfers of financial assets between Level 1 and Level 2	$0
Contingent consideration, discount rate	11.00%
Contingent consideration, weighted average cost of capital	16.00%
Contingent consideration, risk adjustment percentage	5.00%

Acquisition_Details

Acquisition (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jul. 02, 2011
Business Combinations [Abstract]	'	'	'	'
Clinical Force acquisition, cost of acquired entity, cash paid at closing	'	'	'	$5.20
Clinical Force acquisition, contingent consideration, earn-out payments	'	'	'	2.6
Clinical Force acquisition, contingent consideration, at fair value	'	'	'	1.8
Clinical Force acquisition, contingent consideration, description of arrangement	'The earn-out payments were contingent upon the achievement of billing targets for the CTMS application, calculated over three measuring periods beginning at DecemberB 31, 2011 and continuing for each of the next two calendar years thereafter.	'	'	'
Clinical Force acquisition, contingent consideration payment earned sellers	$1.10	$1	$0.50	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Changes in the carrying amount of goodwill	'	'
Beginning balance	$15,382	$15,164
Foreign currency translation adjustments	105	218
Ending balance	$15,487	$15,382

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Intangible assets	'	'
Gross carrying amount	$8,103	$8,058
Accumulated amortization	-7,199	-6,350
Net carrying amount	904	1,708
Acquired technology [Member]	'	'
Intangible assets	'	'
Gross carrying amount	4,129	4,094
Accumulated amortization	-3,481	-2,935
Net carrying amount	648	1,159
Database [Member]	'	'
Intangible assets	'	'
Gross carrying amount	1,900	1,900
Accumulated amortization	-1,900	-1,821
Net carrying amount	0	79
Customer relationships [Member]	'	'
Intangible assets	'	'
Gross carrying amount	2,074	2,064
Accumulated amortization	-1,818	-1,594
Net carrying amount	$256	$470

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets (Details 2) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Annual amortization for the next five years	'
Year ending December 31, 2014	$551
Year ending December 31, 2015	287
Year ending December 31, 2016	47
Year ending December 31, 2017	19
Year ending December 31, 2018	$0

Furniture_Fixtures_and_Equipme2

Furniture, Fixtures and Equipment (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Funiture, fixtures and equipment, gross	$66,818	$42,106
Accumulated depreciation and amortization	-25,589	-31,632
Furniture, fixtures and equipment, net	41,229	10,474
Computer equipment and purchased software [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Funiture, fixtures and equipment, gross	35,123	34,262
Leasehold improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Funiture, fixtures and equipment, gross	24,989	4,283
Furniture and fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Funiture, fixtures and equipment, gross	4,129	1,356
Construction in progress [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Funiture, fixtures and equipment, gross	$2,577	$2,205

Furniture_Fixtures_and_Equipme3

Furniture, Fixtures and Equipment (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Computer equipment and software acquired under capital leases, net	$0.10	$0.10	'
Computer equipment and software acquired under capital leases, accumulated depreciation	-3.3	-10.5	'
Depreciation	6.1	6.1	6.2
Depreciation related to capital leased assets	$0.10	$0.10	$0.70

Debt_Details

Debt (Details) (USD $)	Dec. 31, 2013	Aug. 12, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Convertible senior notes, equity component net of equity issue costs	$60,222	'
Convertible senior notes, principal amount	287,500	287,500
Convertible senior notes, unamortized discount	-57,795	'
Convertible Debt	$229,705	'

Debt_Details_1

Debt (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Debt Instrument [Line Items]	'	'	'
Convertible senior notes, contractual interest expense	$1,118	'	'
Convertible senior notes, amortization of debt issuance costs	533	'	'
Conterible senior notes, amortization of debt discount	4,182	0	0
Convertible senior notes, total interest expense	$5,833	'	'
Convertible senior notes, effective interest rate for period	6.60%	'	'

Debt_Details_Textual

Debt (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Aug. 12, 2013
Debt Instrument [Line Items]	'	'	'	'
Credit facility, line of credit portion	$10,000,000	'	'	'
Unused revolving credit line fee	17,000	35,000	37,000	'
Convertible senior notes, principal amount	287,500,000	'	'	287,500,000
Convertible senior notes, stated interest rate	'	'	'	1.00%
Convertible senior notes, interest payment terms	'Interest is payable semi-annually in arrears on August 1 and February 1 of each year, beginning on February 1, 2014.	'	'	'
Convertible senior notes, maturity	'The Notes mature on August 1, 2018 unless repurchased or converted in accordance with their terms prior to such date. The Company may not redeem the Notes prior to their maturity date.	'	'	'
Convertible senior notes, settlement terms	'Upon conversion of the Notes, the Company may choose to pay or deliver, as applicable, either cash, shares of the Company's common stock, or a combination thereof. If converted, holders of the Notes will receive, at the Company's election, cash and/or shares for the principal amount of the Notes as well as any amounts in excess of principal. The Company intends to settle the principal amount of the Notes in cash if converted.	'	'	'
Convertible senior notes, conversion ratio	17.2286	'	'	'
Convertible senior notes, face amount per note	'	'	'	1,000
Convertible senior notes, conversion price	'	'	'	$58.05
Convertible senior notes, terms of conversion feature	'The initial conversion rate is 17.2286 shares of the Company's common stock per $1,000 principal amount of Notes, which is equivalent to an initial conversion price of approximately $58.05 per share of common stock. The conversion rate will be subject to adjustment upon occurrence of certain events, including, but not limited to, the issuance of stock dividends or payment of cash dividends on the Company's common stock (unless the holders of the Notes participate at the same time and under the same terms as the holders of common stock), or execution of a share split or share combination. Upon conversion, holders of the Notes will not receive any separate cash payment representing accrued and unpaid interest, unless conversion occurs after close of business on a regular record date and prior to the related interest payment date. Holders may convert their Notes at their option at any time prior to the close of business on the business day immediately preceding February 1, 2018 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on December 31, 2013 (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the "measurement period") in which the trading price per $1,000 principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on such trading day; or (3) upon the occurrence of certain corporate events described in the indenture governing the Notes. On or after February 1, 2018 until close of business on the business day immediately preceding the maturity date, holders may convert their Notes at any time, regardless of the foregoing circumstances. If the Company undergoes a fundamental change as defined in the indenture governing the Notes, holders may require the Company to repurchase for cash all of their Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased plus accrued and unpaid interest.	'	'	'
Convertible senior notes, issuance costs	8,100,000	'	'	'
Convertible senior notes, issuance costs related to debt component	6,400,000	'	'	'
Convertible senior notes, issuance costs related to equity component	1,700,000	'	'	'
Convertible senior notes, unamortized debt issuance costs	5,900,000	'	'	'
Convertible senior notes, deferred tax liability recorded	'	'	'	23,100,000
Closing price of the Company's common stock	$60.50	'	'	'
Convertible senior notes, if-converted value in excess of principal	12,200,000	'	'	'
Convertible senior notes, approximate remaining life	'55 months	'	'	'
Convertible Debt [Member] | Fair Value, Inputs, Level 2 [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Convertible senior notes, approximate fair value	$365,100,000	'	'	'

Lease_Commitments_Details

Lease Commitments (Details) (USD $)	Dec. 31, 2013
In Thousands, unless otherwise specified
Future minimum lease payments	'
Operating leases, 2014	$9,197
Operating leases, 2015	12,011
Operating leases, 2016	11,099
Operating leases, 2017	11,111
Operating leases, 2018	11,260
Operating leases, thereafter	59,134
Operating leases, total future minimum payments	113,812
Capital leases, 2014	48
Capital leases, 2015	34
Capital leases, total future minimum payments	82
Capital leases, amount of minimum payments representing interest	$2

Lease_Commitments_Details_Text

Lease Commitments (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Leases [Abstract]	'	'	'
Operating leases, rent expense	$8.70	$4.80	$4.10
Letters of credit in connection with office leases	$5.10	$3.90	'

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of stock-based compensation expense	'	'	'
Total stock-based compensation	$36,143	$10,914	$8,820
Stock options [Member]	'	'	'
Components of stock-based compensation expense	'	'	'
Total stock-based compensation	4,143	4,043	4,238
Restricted stock awards [Member]	'	'	'
Components of stock-based compensation expense	'	'	'
Total stock-based compensation	18,099	6,871	4,582
Performance-based restricted stock units [Member]	'	'	'
Components of stock-based compensation expense	'	'	'
Total stock-based compensation	$13,901	$0	$0

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1) (Stock options [Member])	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock options [Member]	'	'	'
Weighted-average Black-Scholes assumptions used to estimate fair value of stock options granted	'	'	'
Expected volatility	43.00%	46.00%	50.00%
Expected life	'6 years	'6 years	'6 years
Risk-free interest rate	1.48%	0.96%	1.76%
Dividend yield	0.00%	0.00%	0.00%

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Summary of activities and changes in stock option plans	'
Number of shares outstanding at beginning of period	3,578
Weighted-average exercise price outstanding at beginning of period	$9.70
Number of shares granted	473
Weighted-average exercise price granted	$42.04
Number of shares exercised	-1,263
Weighted-average exercise price exercised	$8.28
Number of shares forfeited	-111
Weighted-average exercise price forfeited	$12.44
Number of shares expired	-7
Weighted-average exercise price expired	$3.57
Number of shares outstanding at end of period	2,670
Weighted-average exercise price outstanding at end of period	$16
Weighted average remaining contractual term outstanding at end of period	'7 years 3 months 22 days
Aggregate intrinsic value outstanding at end of period	$118,881
Number of shares exercisable at end of period	1,365
Weighted-average exercise price exercisable at end of period	$8.99
Weighted average remaining contractual term exercisable at end of period	'6 years 1 month 2 days
Aggregate intrinsic value exercisable at end of period	70,295
Number of shares vested and expected to vest at end of period	2,594
Weighted-average exercise price vested and expected to vest at end of period	$15.56
Weighted average remaining contractual term vested and expected to vest at end of period	'7 years 3 months 4 days
Aggregate intrinsic value vested and expected to vest at end of period	$116,637

StockBased_Compensation_Detail3

Stock-Based Compensation (Details 3) (Restricted stock awards [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Restricted stock awards [Member]	'
Summary of nonvested restricted stock awards	'
Nonvested number of shares/units at beginning of period	1,945
Nonvested weighted-average grant-date fair value at beginning of period	$11.54
Granted number of shares/units	945
Granted weighted-average grant-date fair value	$27.24
Vested number of shares/units	-1,032
Vested weighted-average grant-date fair value	$14.83
Forfeited number of shares/units	-186
Forfeited weighted-average grant-date fair value	$14.39
Nonvested number of shares/units at end of period	1,672
Nonvested weighted-average grant-date fair value at end of period	$18.06

StockBased_Compensation_Detail4

Stock-Based Compensation (Details 4) (Performance-based restricted stock units [Member])	12 Months Ended
	Dec. 31, 2013
TSR [Member]	'
Assumptions used to estimate fair value of TSR and Long-Term PBRSUs	'
Expected volatility, Medidata	39.00%
Expected volatility, NASDAQ	15.00%
Risk-free interest rate	0.16%
Expected term	'1 year
Long-Term [Member]	'
Assumptions used to estimate fair value of TSR and Long-Term PBRSUs	'
Expected volatility, Medidata	39.00%
Risk-free interest rate	0.39%
Expected term	'2 years 10 months 10 days

StockBased_Compensation_Detail5

Stock-Based Compensation (Details 5) (Performance-based restricted stock units [Member], USD $)	12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013
Summary of performance based restricted stock units based upon expected performance	'
Nonvested number of shares/units at beginning of period	0
Nonvested weighted-average grant-date fair value at beginning of period	$0
Granted number of shares/units (based on performance at 100% of targeted levels)	1,020
Granted weighted-average grant-date fair value	$29.81
Increase in Units Due to Expected Performance	723
Adjustment Due To Expected Performance Weighted Average Grant Date Fair Value	$28.35
Vested number of shares/units	0
Vested weighted-average grant-date fair value	$0
Forfeited number of shares/units	-41
Forfeited weighted-average grant-date fair value	$30.07
Nonvested number of shares/units at end of period	1,702
Nonvested weighted-average grant-date fair value at end of period	$29.18
Revenue [Member]	'
Summary of performance based restricted stock units based upon expected performance	'
Nonvested number of shares/units at beginning of period	0
Granted number of shares/units (based on performance at 100% of targeted levels)	227
Increase in Units Due to Expected Performance	227
Vested number of shares/units	0
Forfeited number of shares/units	0
Nonvested number of shares/units at end of period	454
TSR [Member]	'
Summary of performance based restricted stock units based upon expected performance	'
Nonvested number of shares/units at beginning of period	0
Granted number of shares/units (based on performance at 100% of targeted levels)	113
Increase in Units Due to Expected Performance	114
Vested number of shares/units	0
Forfeited number of shares/units	0
Nonvested number of shares/units at end of period	227
Long-Term [Member]	'
Summary of performance based restricted stock units based upon expected performance	'
Nonvested number of shares/units at beginning of period	0
Granted number of shares/units (based on performance at 100% of targeted levels)	646
Increase in Units Due to Expected Performance	407
Vested number of shares/units	0
Forfeited number of shares/units	-41
Nonvested number of shares/units at end of period	1,012
Sales [Member]	'
Summary of performance based restricted stock units based upon expected performance	'
Nonvested number of shares/units at beginning of period	0
Granted number of shares/units (based on performance at 100% of targeted levels)	34
Decrease in Units Due To Expected Performance	-25
Vested number of shares/units	'
Forfeited number of shares/units	0
Nonvested number of shares/units at end of period	9

StockBased_Compensation_Detail6

Stock-Based Compensation (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Stock based compensation (Textual) [Abstract]	'	'	'
Total stock-based compensation	$36,143,000	$10,914,000	$8,820,000
2000 Stock Option Plan [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Award vesting terms	'The majority of the options are vested 25% one year from the grant date and 75% ratably over the next three years and expire after ten years.	'	'
2009 Long-Term Incentive Plan [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Award vesting terms	'vest monthly over four years	'	'
Number of shares of common stock originally reserved for issuance under share based compensation plan	5,000,000	'	'
Number of shares of common stock issuable under share based compensation plan as amended	11,000,000	'	'
Stock options [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Weighted-average grant-date fair value of stock options granted	$18.06	$6.44	$5.19
Total intrinsic value of stock options exercised	38,400,000	20,000,000	6,200,000
Unrecognized compensation cost related to non-vested stock-based compensation awards granted	12,500,000	'	'
Weighted-average remaining period over which cost is expected to be recognized	'2 years 6 months 22 days	'	'
Total fair value of shares vested	3,500,000	3,900,000	4,300,000
Total stock-based compensation	4,143,000	4,043,000	4,238,000
Restricted stock awards [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Unrecognized compensation cost related to non-vested stock-based compensation awards granted	23,100,000	'	'
Weighted-average remaining period over which cost is expected to be recognized	'2 years 2 months 12 days	'	'
Total fair value of shares vested	44,600,000	8,900,000	4,800,000
Total stock-based compensation	18,099,000	6,871,000	4,582,000
Performance-based restricted stock units [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Unrecognized compensation cost related to non-vested stock-based compensation awards granted	33,100,000	'	'
Weighted-average remaining period over which cost is expected to be recognized	'2 years 1 month 5 days	'	'
Total stock-based compensation	13,901,000	0	0
Performance-based restricted stock units [Member] | Revenue [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Target number of performance based restricted stock units granted during the period	227,076	'	'
Award terms	'based on revenue for the year ending December 31, 2013 relative to the Company's revenue guidance and a minimum profitability condition, vesting annually over three years commencing on the first anniversary of the grant date, with the number of PBRSUs ultimately earned ranging from zero to 200% of the original award	'	'
Total stock-based compensation	3,300,000	'	'
Performance-based restricted stock units [Member] | TSR [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Target number of performance based restricted stock units granted during the period	113,538	'	'
Award terms	'based on the Company's total stockholder return ("TSR") relative to that of the NASDAQ Composite Index for the year ending December 31, 2013, vesting annually over three years commencing on the first anniversary of the grant date, with the number of PBRSUs ultimately earned ranging from zero to 200% of the original award	'	'
Total stock-based compensation	1,200,000	'	'
Performance-based restricted stock units [Member] | Long-Term [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Target number of performance based restricted stock units granted during the period	645,528	'	'
Award terms	'based on the Company's compound annual growth rate of revenue ("CAGR"), as defined in the grant agreement, and the Company's absolute TSR over the three-year performance period ending December 31, 2015, vesting in full on December 31, 2015, with the number of PBRSUs ultimately earned ranging from zero to 300% of the original award	'	'
Total stock-based compensation	9,300,000	'	'
Performance-based restricted stock units [Member] | Sales [Member]	'	'	'
Stock based compensation (Textual) [Abstract]	'	'	'
Target number of performance based restricted stock units granted during the period	34,426	'	'
Award terms	'based on the achievement of certain sales performance goals for the six months ending December 31, 2013, vesting annually over four years commencing on the first anniversary of the grant date, with the number of PBRSUs ultimately earned ranging from zero to 100% of the original award.	'	'
Total stock-based compensation	$100,000	'	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Loss (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Accumulated other comprehensive loss	'	'	'
Beginning balance	($63)	($362)	'
Other comprehensive income (loss), net of tax	-136	299	-245
Ending balance	-199	-63	-362
Unrealized gains (losses) on available for sale securities	'	'	'
Accumulated other comprehensive loss	'	'	'
Beginning balance	-10	-27	'
Other comprehensive income (loss), net of tax	-62	17	'
Ending balance	-72	-10	'
Foreign currency translation adjustments	'	'	'
Accumulated other comprehensive loss	'	'	'
Beginning balance	-53	-335	'
Other comprehensive income (loss), net of tax	-74	282	'
Ending balance	($127)	($53)	'

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Loss (Details Textual) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Accumulated Other Comprehensive Income [Abstract]	'	'
Reclassifications from accumulated other comprehensive income	$2	$0

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Numerator	'	'	'	'	'	'	'	'	'	'	'
Net income	$582	$5,273	$5,106	$5,700	$6,593	$4,053	$3,604	$3,770	$16,661	$18,020	$39,398
Denominator for basic earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Weighted average common shares outstanding	'	'	'	'	'	'	'	'	51,060	49,092	47,292
Denominator for diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Weighted average common shares outstanding with assumed conversion	'	'	'	'	'	'	'	'	54,118	50,938	49,314
Basic earnings per share	$0.01	$0.10	$0.10	$0.11	$0.13	$0.08	$0.07	$0.08	$0.33	$0.37	$0.83
Diluted earnings per share	$0.01	$0.10	$0.09	$0.11	$0.13	$0.08	$0.07	$0.07	$0.31	$0.35	$0.80
Total number of anti-dilutive shares of stock options and nonvested stock excluded from calculation of diluted earnings per share	'	'	'	'	'	'	'	'	237	716	972
Stock options [Member]	'	'	'	'	'	'	'	'	'	'	'
Denominator for diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Dilutive potential common shares	'	'	'	'	'	'	'	'	1,581	1,290	1,520
Nonvested restricted stock awards [Member]	'	'	'	'	'	'	'	'	'	'	'
Denominator for diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Dilutive potential common shares	'	'	'	'	'	'	'	'	1,030	556	502
Performance-based restricted stock units [Member]	'	'	'	'	'	'	'	'	'	'	'
Denominator for diluted earnings per share:	'	'	'	'	'	'	'	'	'	'	'
Dilutive potential common shares	'	'	'	'	'	'	'	'	447	0	0

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Current expense:	'	'	'
Federal and state	$1,372	$5,827	$4,509
Foreign	1,165	1,099	751
Current expense	2,537	6,926	5,260
Deferred expense (benefit):	'	'	'
Federal and state	2,381	3,505	3,355
Foreign	-439	-178	-124
Valuation allowance	-2,758	-204	-24,924
Deferred (benefit) expense	-816	3,123	-21,693
Total income tax expense (benefit)	$1,721	$10,049	($16,433)

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Reconciliation of income taxes computed at federal statutory rate	'	'	'
Tax computed at federal statutory rate	$6,434	$9,824	$8,038
Increase (decrease) in income taxes resulting from:	'	'	'
Valuation allowance	-2,758	-204	-24,558
U.S. R&D tax credit	-2,833	0	-2,516
Recognition of uncertain tax position	269	461	342
Stock-based compensation	-151	-40	353
Undistributed earnings from foreign subsidiaries	1,737	1,275	665
State tax expense, net of federal benefit	667	747	1,026
Excess compensation deduction	950	0	0
Non-deductible bonuses	120	102	184
Non-deductible items	-3	67	-6
Foreign tax rate differential	-339	-205	39
Domestic production activities deduction	-665	-232	0
Foreign tax credit	-1,737	-1,051	0
Other	30	-695	0
Total income tax expense (benefit)	$1,721	$10,049	($16,433)

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Assets:	'	'
Net operating loss carryforwards	$4,961	$5,769
Deferred revenue	2,502	7,517
Depreciable and amortizable assets	6,792	6,407
U.S. and state R&D tax credits	403	281
Foreign tax credit	107	2,758
Stock-based compensation	9,305	3,651
Debt issuance costs	618	0
Other	5,817	2,033
Gross deferred tax assets	30,505	28,416
Liabilities:	'	'
Depreciatble and amortizable assets	-12,234	-6,945
Management fee	-222	-310
Foreign exchange translation	-139	-153
Convertible notes	-22,196	0
Other	-355	-375
Gross deferred tax liabilities	-35,146	-7,783
Less: valuation allowance	0	-2,758
Net deferred tax (liabilities) assets	-4,641	17,875
Net current deferred tax assets	665	7,465
Net long-term deferred tax assets	345	11,055
Net current deferred tax liabilities (included in accrued expenses and other)	0	-21
Net long-term deferred tax liabilities	($5,651)	($624)

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Components of income before income tax expense	'	'	'
U.S. income	$14,549	$25,064	$21,731
Non-U.S. income	3,833	3,005	1,234
Income before income taxes	$18,382	$28,069	$22,965

Income_Taxes_Details_4

Income Taxes (Details 4) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Unrecognized tax benefits roll forward	'	'	'
Gross unrecognized tax benefits as of beginning of period	$2,946	$2,109	$0
Increases based on tax positions related to the current year	429	229	521
Increases related to tax positions from prior fiscal years	734	608	1,588
Gross unrecognized tax benefits as of end of period	$4,109	$2,946	$2,109

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
[Line Items]	'	'	'
Tax credits not included in deferred tax assets	$8.80	$4.20	'
One-time tax benefit from reveresal of valuation allowance	'	'	19
Unrecognized tax benefits that would affect the Company's effective tax rate if recognized	4.1	'	'
Recognized interest and penalties	0.2	0.2	0
Description of tax examination	'The Companybs federal income tax returns for the 2000 through 2012 tax years remain open to examination by the IRS in their entirety, except for its 2007 and 2010 tax returns. The examination of the Company's 2007 and 2010 federal tax returns were completed in 2010 and 2013, respectively. No adjustments to the tax returns were proposed by the IRS in either examination. In addition, the Companybs state income tax returns for the 2000 through 2012 tax years also remain open to examination by state taxing authorities.	'	'
Federal	'	'	'
[Line Items]	'	'	'
Operating loss carryforwards	36.6	12	'
Operating loss carryforwards, expiration dates	'2020 through 2033	'2019 through 2028	'
Operating loss carryforwards, limitations on use	'Certain NOLs obtained through the acquisition of Fast Track in 2008 are subject to limitations under Section 382 of the Internal Revenue Code	'	'
State and local	'	'	'
[Line Items]	'	'	'
Operating loss carryforwards	$22.10	$12.20	'
Operating loss carryforwards, expiration dates	'2020 through 2033	'2019 through 2028	'

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Commitments and Contingencies (Textual) [Abstract]	'	'	'
Description of 401(k) plan	'Under the 401(k) Plan, eligible employees are able to contribute up to 15% of their compensation not to exceed the maximum IRS annual deferral amount. The Company provides a 50% match of the first 4% of eligible compensation contributed each period by the employees. The maximum match by the Company is therefore 2% of eligible compensation.	'	'
Company 401(k) matching contributions	$1.40	$1.20	$0.90
2011 Datasci settlement	'	'	$6.30
Change in control agreements, period following change in control for payments to be made upon involuntary termination of employment	'2 years	'	'
Change in control agreements, period for continuation of health benefits	'12 months	'	'

Unaudited_Selected_Quarterly_F2

Unaudited Selected Quarterly Financial Data (Details) (USD $)	3 Months Ended								12 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Unaudited Selected Quarterly Financial Information [Abstract]	'	'	'	'	'	'	'	'	'	'	'
Total revenues	$74,575	$70,946	$68,069	$63,259	$58,630	$55,845	$53,513	$50,359	$276,849	$218,347	$184,459
Gross profit	55,977	53,684	51,149	46,130	42,257	39,946	37,738	35,744	206,940	155,685	131,628
Operating income	-1,516	9,476	8,836	7,092	9,250	6,839	5,688	6,116	23,888	27,893	22,557
Net income	$582	$5,273	$5,106	$5,700	$6,593	$4,053	$3,604	$3,770	$16,661	$18,020	$39,398
Basic earnings per share	$0.01	$0.10	$0.10	$0.11	$0.13	$0.08	$0.07	$0.08	$0.33	$0.37	$0.83
Diluted earnings per share	$0.01	$0.10	$0.09	$0.11	$0.13	$0.08	$0.07	$0.07	$0.31	$0.35	$0.80

Valuation_and_Qualifying_Accou1

Valuation and Qualifying Accounts (Details) (Allowance for Doubtful Accounts, Current [Member], USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Allowance for Doubtful Accounts, Current [Member]	'	'	'
Movement in valuation allowances and reserves	'	'	'
Balance at beginning of period	$747	$882	$308
Charged to costs and expenses	657	165	410
Charged to other accounts	0	239	225
Deductions	-349	-539	-61
Balance at end of period	$1,055	$747	$882